DLL3 / CD3 binding proteins for cancer therapy

By binding to DLL3 and CD3 by bispecific T cell binding proteins, T cells are activated against targeting tumor cells, solving the problem of limited effectiveness of existing DLL3 targeted therapies, and achieving efficient treatment for diseases such as SCLC and glioblastoma .

CN112513092BActive Publication Date: 2024-11-08BOEHRINGER INGELHEIM INT GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980051335.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-02-26
Filing Date
2019-06-07
Publication Date
2024-11-08
Estimated Expiration
2039-06-07

Smart Images

  • Figure CN112513092B_ABST
    Figure CN112513092B_ABST
Patent Text Reader

Abstract

The present invention relates to novel DLL3 / CD3 binding proteins. The present invention also relates to the use of such proteins or compositions thereof, in particular for therapeutic purposes in the field of cancer diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[Background of the invention]

Technical field

[0001] The present invention relates to multispecific binding proteins comprising a first antigen-binding unit specific for DLL3 and a second antigen-binding unit specific for CD3. The present invention also relates to nucleic acids encoding such binding proteins; methods for preparing such binding proteins; host cells that express or are capable of expressing such binding proteins; compositions comprising such binding proteins; and uses of such binding proteins or such compositions, particularly for therapeutic purposes in the field of cancer. [Background Technology]

[0003] DLL3 belongs to the type I transmembrane protein of the Notch ligand family. DLL3 is primarily involved in somitogenesis, where it is primarily localized to the Golgi apparatus and acts as an inhibitor of Notch signaling, compared to other DLL family members DLL1 and DLL4, which are located on the cell surface. Only in cancer cells that overexpress DLL3 do some DLL3 molecules escape to the cell surface (Dylla, Molecular & Cellular Oncology 2016, Vol. 3, No. 2). DLL3 has been identified as a tumor-specific target using several methods, such as LC / MS analysis of tumor tissue (WO 2014 / 125273), RNA sequencing (WO 2017 / 021349), and immunohistochemistry (Saunders et al., Sci Transl Med. 2015 Aug 26; 7(302):302ra136; Saunders et al., AACR 2017; WO 2013 / 126746).

[0004] DLL3 expression has been described in neuroendocrine tumors such as large cell neuroendocrine carcinoma (LCNEC), small cell lung cancer (SCLC), neuroendocrine prostate cancer, neuroendocrine pancreatic cancer, and glioblastoma (Saunders et al., Sci Transl Med. 2015 Aug 26;7(302):302ra136; Saunders et al., AACR 2017).

[0005] SCLC represents an indication with a very high medical need. SCLC accounts for 13% of lung cancer diagnoses and has a poorer prognosis than NSCLC. Conventional treatment for these cancers primarily consists of chemotherapy, radiation therapy, surgery, or a combination thereof, with no available targeted therapies. Despite high initial response rates to chemotherapy, many patients rapidly relapse with chemotherapy-resistant disease, leaving few treatment options available. While treatment for these cancers has improved over the past few years, the overall survival rate for these tumor types has remained unchanged, and therefore, there remains an unmet need for more targeted and potent therapies.

[0006] One targeted therapy approach is offered by antibody-drug conjugates (ADCs). However, for DLL3, this strategy is not preferred due to its low cell surface expression and high resistance to chemotherapy. Because most patients relapse after chemotherapy and due to the low expression of DLL3 on the cell surface, targeting DLL3 with ADCs can be limited. Furthermore, ADC approaches often suffer from off-target toxicities caused by the free drug due to linker instability or degradation.

[0007] Attempts have been made to target DLL3 in combination with the targeting of other proteins. For example, WO 2017 / 021349 describes a bispecific antibody construct that binds to both human DLL3 on the surface of target cells and human CD3 on the surface of T cells. However, such approaches have not proven successful, and to date, no targeted therapies are available for SCLC, glioblastoma, or other tumors that express DLL3.

[0008] In view of the poor outlook for patients with such cancers, there is a need to identify more effective therapies, particularly those with improved tolerability. Therefore, one object of the present invention is to provide pharmacologically active agents, compositions and / or treatment methods that provide certain advantages over currently used and / or known agents, compositions and / or methods in the art. These advantages include in vivo efficacy, improved therapeutic and pharmacological properties, increased specificity, improved safety profiles, fewer side effects, reduced immunogenicity, and other favorable properties, such as improved ease of preparation or reduced cost of goods, higher stability / longer half-life, and less frequent dosing regimen requirements, particularly compared to drug candidates known in the art. [Summary of the invention]

[0009] The present invention is based on a bispecific T cell engagement approach that employs a multispecific binding protein having a binding arm that binds to CD3 on T cells and a binding arm that binds to DLL3 on the cell surface of tumor cells. By simultaneously binding to both T cells and tumor cells, the T cell engager forces the formation of a cytolytic synapse between the two cells, thereby selectively redirecting T cell activity toward targeted tumor cells.

[0010] In one aspect, the present invention provides a multispecific binding protein comprising a first antigen binding unit that specifically binds to DLL3 and a second antigen binding unit that specifically binds to CD3, wherein the first antigen binding unit that specifically binds to DLL3 is selected from the group consisting of i) to xviii):

[0011] i) an antigen-binding unit comprising: a light chain CDR comprising the amino acid sequences of SEQ ID NO: 1 (CDR1), SEQ ID NO: 2 (CDR2), and SEQ ID NO: 3 (CDR3); and a heavy chain CDR comprising the amino acid sequences of SEQ ID NO: 4 (CDR1), SEQ ID NO: 5 (CDR2), and SEQ ID NO: 6 (CDR3);

[0012] ii) an antigen-binding unit comprising: a light chain CDR comprising the amino acid sequence of SEQ ID NO: 7 (CDR1), SEQ ID NO: 8 (CDR2), and SEQ ID NO: 9 (CDR3); and a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 10 (CDR1), SEQ ID NO: 11 (CDR2), and SEQ ID NO: 12 (CDR3);

[0013] iii) an antigen-binding unit comprising: a light chain CDR comprising the amino acid sequence of SEQ ID NO: 13 (CDR1), SEQ ID NO: 14 (CDR2), and SEQ ID NO: 15 (CDR3); and a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 16 (CDR1), SEQ ID NO: 17 (CDR2), and SEQ ID NO: 18 (CDR3);

[0014] iv) an antigen-binding unit comprising: a light chain CDR comprising the amino acid sequences of SEQ ID NO: 19 (CDR1), SEQ ID NO: 20 (CDR2), and SEQ ID NO: 21 (CDR3); and a heavy chain CDR comprising the amino acid sequences of SEQ ID NO: 22 (CDR1), SEQ ID NO: 23 (CDR2), and SEQ ID NO: 24 (CDR3);

[0015] v) an antigen-binding unit comprising: a light chain CDR comprising the amino acid sequences of SEQ ID NO: 25 (CDR1), SEQ ID NO: 26 (CDR2), and SEQ ID NO: 27 (CDR3); and a heavy chain CDR comprising the amino acid sequences of SEQ ID NO: 28 (CDR1), SEQ ID NO: 29 (CDR2), and SEQ ID NO: 30 (CDR3);

[0016] vi) an antigen-binding unit comprising: a light chain CDR comprising the amino acid sequences of SEQ ID NO: 31 (CDR1), SEQ ID NO: 32 (CDR2), and SEQ ID NO: 33 (CDR3); and a heavy chain CDR comprising the amino acid sequences of SEQ ID NO: 34 (CDR1), SEQ ID NO: 35 (CDR2), and SEQ ID NO: 36 (CDR3);

[0017] vii) an antigen-binding unit comprising: a light chain CDR comprising the amino acid sequences of SEQ ID NO: 133 (CDR1), SEQ ID NO: 134 (CDR2), and SEQ ID NO: 135 (CDR3); and a heavy chain CDR comprising the amino acid sequences of SEQ ID NO: 136 (CDR1), SEQ ID NO: 137 (CDR2), and SEQ ID NO: 138 (CDR3);

[0018] viii) an antigen-binding unit comprising: a light chain CDR comprising the amino acid sequences of SEQ ID NO: 139 (CDR1), SEQ ID NO: 140 (CDR2), and SEQ ID NO: 141 (CDR3); and a heavy chain CDR comprising the amino acid sequences of SEQ ID NO: 142 (CDR1), SEQ ID NO: 143 (CDR2), and SEQ ID NO: 144 (CDR3);

[0019] ix) an antigen-binding unit comprising: a light chain CDR comprising the amino acid sequence of SEQ ID NO: 145 (CDR1), SEQ ID NO: 146 (CDR2), and SEQ ID NO: 147 (CDR3); and a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 148 (CDR1), SEQ ID NO: 149 (CDR2), and SEQ ID NO: 150 (CDR3);

[0020] x) an antigen-binding unit comprising: a light chain CDR comprising the amino acid sequences of SEQ ID NO: 151 (CDR1), SEQ ID NO: 152 (CDR2), and SEQ ID NO: 153 (CDR3); and a heavy chain CDR comprising the amino acid sequences of SEQ ID NO: 154 (CDR1), SEQ ID NO: 155 (CDR2), and SEQ ID NO: 156 (CDR3);

[0021] xi) an antigen-binding unit comprising: a light chain CDR comprising the amino acid sequence of SEQ ID NO: 157 (CDR1), SEQ ID NO: 158 (CDR2), and SEQ ID NO: 159 (CDR3); and a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 160 (CDR1), SEQ ID NO: 161 (CDR2), and SEQ ID NO: 162 (CDR3);

[0022] xii) an antigen-binding unit comprising: a light chain CDR comprising the amino acid sequences of SEQ ID NO: 163 (CDR1), SEQ ID NO: 164 (CDR2), and SEQ ID NO: 165 (CDR3); and a heavy chain CDR comprising the amino acid sequences of SEQ ID NO: 166 (CDR1), SEQ ID NO: 167 (CDR2), and SEQ ID NO: 168 (CDR3);

[0023] xiii) an antigen-binding unit comprising: a light chain CDR comprising the amino acid sequences of SEQ ID NO: 169 (CDR1), SEQ ID NO: 170 (CDR2), and SEQ ID NO: 171 (CDR3); and a heavy chain CDR comprising the amino acid sequences of SEQ ID NO: 172 (CDR1), SEQ ID NO: 173 (CDR2), and SEQ ID NO: 174 (CDR3);

[0024] xiv) an antigen-binding unit comprising: a light chain CDR comprising the amino acid sequences of SEQ ID NO: 175 (CDR1), SEQ ID NO: 176 (CDR2), and SEQ ID NO: 177 (CDR3); and a heavy chain CDR comprising the amino acid sequences of SEQ ID NO: 178 (CDR1), SEQ ID NO: 179 (CDR2), and SEQ ID NO: 180 (CDR3);

[0025] xv) an antigen-binding unit comprising: a light chain CDR comprising the amino acid sequences of SEQ ID NO: 181 (CDR1), SEQ ID NO: 182 (CDR2), and SEQ ID NO: 183 (CDR3); and a heavy chain CDR comprising the amino acid sequences of SEQ ID NO: 184 (CDR1), SEQ ID NO: 185 (CDR2), and SEQ ID NO: 186 (CDR3);

[0026] xvi) an antigen-binding unit comprising: a light chain CDR comprising the amino acid sequences of SEQ ID NO: 187 (CDR1), SEQ ID NO: 188 (CDR2), and SEQ ID NO: 189 (CDR3); and a heavy chain CDR comprising the amino acid sequences of SEQ ID NO: 190 (CDR1), SEQ ID NO: 191 (CDR2), and SEQ ID NO: 192 (CDR3);

[0027] xvii) an antigen-binding unit comprising: a light chain CDR comprising the amino acid sequences of SEQ ID NO: 193 (CDR1), SEQ ID NO: 194 (CDR2), and SEQ ID NO: 195 (CDR3); and a heavy chain CDR comprising the amino acid sequences of SEQ ID NO: 196 (CDR1), SEQ ID NO: 197 (CDR2), and SEQ ID NO: 198 (CDR3); and

[0028] xviii) an antigen-binding unit comprising: a light chain CDR comprising the amino acid sequence of SEQ ID NO: 199 (CDR1), SEQ ID NO: 200 (CDR2) and SEQ ID NO: 201 (CDR3); and a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 202 (CDR1), SEQ ID NO: 203 (CDR2) and SEQ ID NO: 204 (CDR3).

[0029] In some embodiments of the binding protein of the present invention, the first antigen binding unit that specifically binds to DLL3 comprises a first light chain variable domain and a first heavy chain variable domain and is selected from the group consisting of i) to xviii):

[0030] i) an antigen-binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 37 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 38;

[0031] ii) an antigen-binding unit comprising: a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 39 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 40;

[0032] iii) an antigen-binding unit comprising: a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 41 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 42;

[0033] iv) an antigen-binding unit comprising: a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 43 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 44;

[0034] v) an antigen-binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 45 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 46;

[0035] vi) an antigen-binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 47 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 48;

[0036] vii) an antigen-binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 205 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 206;

[0037] viii) an antigen-binding unit comprising: a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 207 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 208;

[0038] ix) an antigen-binding unit comprising: a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 209 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 210;

[0039] x) an antigen-binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 211 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 212;

[0040] xi) an antigen-binding unit comprising: a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 213 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 214;

[0041] xii) an antigen-binding unit comprising: a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 215 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 216;

[0042] xiii) an antigen-binding unit comprising: a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 217 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 218;

[0043] xiv) an antigen-binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 219 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 220;

[0044] xv) an antigen-binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 221 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 222;

[0045] xvi) an antigen-binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 223 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 224;

[0046] xvii) an antigen-binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 225 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 226; and

[0047] xviii) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 227 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 228.

[0048] In some embodiments of the binding protein of the present invention, the second antigen binding unit that specifically binds to CD3 is selected from the group consisting of i) to iii):

[0049] i) an antigen-binding unit comprising: a light chain CDR comprising the amino acid sequence of SEQ ID NO: 55 (CDR1), SEQ ID NO: 56 (CDR2), and SEQ ID NO: 57 (CDR3); and a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 58 (CDR1), SEQ ID NO: 59 (CDR2), and SEQ ID NO: 60 (CDR3);

[0050] ii) an antigen-binding unit comprising: a light chain CDR comprising the amino acid sequence of SEQ ID NO: 61 (CDR1), SEQ ID NO: 62 (CDR2), and SEQ ID NO: 63 (CDR3); and a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 64 (CDR1), SEQ ID NO: 65 (CDR2), and SEQ ID NO: 66 (CDR3); and

[0051] iii) an antigen-binding unit comprising: a light chain CDR comprising the amino acid sequence of SEQ ID NO: 96 (CDR1), SEQ ID NO: 97 (CDR2) and SEQ ID NO: 98 (CDR3); and a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 99 (CDR1), SEQ ID NO: 100 (CDR2) and SEQ ID NO: 101 (CDR3).

[0052] In some embodiments of the binding protein of the present invention, the second antigen binding unit that specifically binds to CD3 comprises a second light chain variable domain and a second heavy chain variable domain and is selected from the group consisting of:

[0053] i) an antigen-binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 67 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 68;

[0054] ii) an antigen-binding unit comprising: a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 69 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 70; and

[0055] iii) an antigen-binding unit comprising: a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 102 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 103.

[0056] In some embodiments of the present invention, a first antigen-binding unit that specifically binds to DLL3 comprises, from its N-terminus to its C-terminus: a first light chain variable domain, a first light chain constant domain, a first peptide linker, a first heavy chain variable domain, and a first heavy chain constant CH1 domain; and a second antigen-binding unit that specifically binds to CD3 comprises, from its N-terminus to its C-terminus: a second light chain variable domain, a second light chain constant domain, a second peptide linker, a second heavy chain variable domain, and a second heavy chain constant CH1 domain. In some embodiments of the present invention, the first and / or second peptide linkers comprise 26 to 42 amino acids, preferably any one of 30 to 40 amino acids, 34 to 40 amino acids, or 36 to 39 amino acids, more preferably 38 amino acids. In some embodiments of the present invention, the first linker and / or the second linker is a Gly-Ser linker, preferably comprising the amino acid sequence of SEQ ID NO: 89, more preferably the first and second peptide linkers comprise the same sequence.

[0057] In some embodiments, the binding protein of the present invention further comprises first and second Fc domains, the first Fc domain is covalently linked to the first antigen binding unit, and the second Fc domain is covalently linked to the second antigen binding unit.

[0058] In some embodiments of the present invention,

[0059] i) the first Fc domain comprises a tyrosine (Y) at position 366 [T366Y], and the second Fc domain comprises a threonine (T) at position 407 [Y407T], or

[0060] ii) the first Fc domain comprises a tryptophan (W) at position 366 [T366W], and the second Fc domain comprises a serine (S) at position 366 [T366S], an alanine (A) at position 368 [L368A], and a valine (V) at position 407 [Y407V], or

[0061] iii) the second Fc domain comprises a tyrosine (Y) at position 366 [T366Y], and the first Fc domain comprises a threonine (T) at position 407 [Y407T], or

[0062] iv) the second Fc domain comprises a tryptophan (W) at position 366 [T366W], and the first Fc domain comprises a serine (S) at position 366 [T366S], an alanine (A) at position 368 [L368A], and a valine (V) at position 407 [Y407V],

[0063] Preferably, the first or the second Fc domain further comprises an arginine at position 435 [H435R] and a phenylalanine at position 436 [Y436F]. In some embodiments, the first and / or second Fc domain further comprises an alanine at position 234 [L234A] and an alanine at position 235 [L235A]. In some embodiments, the first and second light chain constant domains comprise human kappa or lambda domains.

[0064] In a preferred embodiment, the binding protein of the invention comprises: a first polypeptide chain that specifically binds to DLL3, comprising an amino acid sequence selected from the group consisting of SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:241, SEQ ID NO:242, SEQ ID NO:243, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO:246, SEQ ID NO:247, SEQ ID NO:248, SEQ ID NO:249, SEQ ID NO:250, SEQ ID NO:251, and SEQ ID NO:252; and a second polypeptide chain that specifically binds to CD3, comprising the amino acid sequence of SEQ ID NO:79, SEQ ID NO:80, or SEQ ID NO:105.

[0065] In another aspect, the present invention provides isolated nucleic acid molecules that i) encode the first antigen binding unit and / or the second antigen binding unit of a protein of the present invention, optionally further encoding the first and / or second Fc domain, or ii) encode the first and / or second polypeptide chain of a protein of the present invention. Other aspects provided herein are expression vectors comprising the nucleic acid molecules of the present invention, host cells transfected with such expression vectors, and methods for producing the proteins of the present invention.

[0066] In another aspect of the present invention, provided herein is a multispecific binding protein comprising a first polypeptide chain that specifically binds to DLL3 and a second polypeptide chain that specifically binds to CD3, wherein the first polypeptide chain comprises a first light chain, a first linker, and a first heavy chain, and the second polypeptide chain comprises a second light chain, a second linker, and a second heavy chain, preferably, the C-terminus of the first light chain is covalently bonded to the N-terminus of the first heavy chain via the first peptide linker, and the C-terminus of the second light chain is covalently bonded to the N-terminus of the second heavy chain via the second peptide linker.

[0067] In some embodiments of the binding proteins of the invention, the first polypeptide chain that specifically binds to DLL3 comprises a light chain variable domain and a heavy chain variable domain, wherein the light chain variable domain and the heavy chain variable domain comprise CDR sequences and / or VH / VL sequences as defined for the antigen binding unit of DLL3#1, DLL3#2, DLL3#3, DLL3#4, DLL3#5, DLL3#6, DLL3#7, DLL3#8, DLL3#9, DLL3#10, DLL3#11, DLL3#12, DLL3#13, DLL3#14, DLL3#15, DLL3#16, DLL3#17, or DLL3#18 as described herein. In some embodiments, the second polypeptide chain that specifically binds to CD3 comprises a light chain variable domain and a heavy chain variable domain, wherein the light chain variable domain and the heavy chain variable domain comprise CDR sequences and / or VH / VL sequences as defined for the antigen binding unit of CD3#1, CD3#2, or CD3#3 as described herein.

[0068] Other aspects, embodiments, uses and methods relating to the binding proteins of the present invention will become apparent from the following detailed description of the invention and the appended claims.

[0069] The present invention provides novel binding proteins that allow for more efficient treatment of cancers expressing DLL3, such as SCLC, glioblastoma or DLL3-expressing neuroendocrine tumors. Sequence Listing <110> Boehringer Ingelheim International GmbH <120> DLL3 / CD3 binding proteins for cancer treatment <130> 12-0431-WO-1 <160> 265 <170> BiSSAP 1.2 <210> 1 <211> 12 <212> PRT <213> Artificial sequence <220> <223> DLL3# 1LCCDR1 <400> 1 Arg Ala Ser Gln Ser Val Ser Ser Asn Phe Leu Val 1 5 10 <210> 2 <211> 7 <212> PRT <213> Artificial sequence <220> <223> DLL3#1 LCCDR2 <400> 2 Gly Ala Ser Thr Arg Ala Ser 1 5 <210> 3 <211> 9 <212> PRT <213> Artificial sequence <220> <223> DLL3#1 LCCDR3 <400> 3 Gln Gln Tyr Gly Asp Ser Pro Tyr Thr 1 5 <210> 4 <211> 10 <212> PRT <213> Artificial sequence <220> <223> DLL3#1 HCCDR1 <400> 4 Gly Asn Thr Phe Thr Asn Tyr Tyr Met His 1 5 10 <210> 5 <211> 17 <212> PRT <213> Artificial sequence <220> <223> DLL3#1 HCCDR2 <400> 5 Ile Ile Asp Pro Ser Val Gly Ser Lys Ser Tyr Ala Gln Lys Phe Leu 1 5 10 15 Gly <210> 6 <211> 12 <212> PRT <213> Artificial sequence <220> <223> DLL3#1 HCCDR3 <400> 6 Ala Gly Lys Arg Phe Gly Glu Ser Tyr Phe Asp Tyr 1 5 10 <210> 7 <211> 11 <212> PRT <213> Artificial sequence <220> <223> DLL3#2 LCCDR1 <400> 7 Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala 1 5 10 <210> 8 <211> 7 <212> PRT <213> Artificial sequence <220> <223> DLL3#2 LCCDR1 <400> 8 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 9 <211> 9 <212> PRT <213> Artificial sequence <220> <223> DLL3#2 LCCDR1 <400> 9 Leu Gln His Asn Ser Ser Pro Tyr Thr 1 5 <210> 10 <211> 10 <212> PRT <213> Artificial sequence <220> <223> DLL3#2 HCCDR1 <400> 10 Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His 1 5 10 <210> 11 <211> 17 <212> PRT <213> Artificial sequence <220> <223> DLL3#2 HCCDR2 <400> 11 Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 12 <211> 15 <212> PRT <213> Artificial sequence <220> <223> DLL3#2 HCCDR3 <400> 12 Gly Glu Ala Val Gly Gly Asn Tyr Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 13 <211> 11 <212> PRT <213> Artificial sequence <220> <223> DLL3#3 LCCDR1 <400> 13 Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Val 1 5 10 <210> 14 <211> 7 <212> PRT <213> Artificial sequence <220> <223> DLL3#3 LCCDR2 <400> 14 Ala Val Ser Ser Leu Tyr Ser 1 5 <210> 15 <211> 9 <212> PRT <213> Artificial sequence <220> <223> DLL3#3 LCCDR3 <400> 15 Leu Gln His Asp Ser Tyr Pro Tyr Thr 1 5 <210> 16 <211> 10 <212> PRT <213> Artificial sequence <220> <223> DLL3#3 HCCDR1 <400> 16 Gly Tyr Thr Phe Thr Ser Tyr Tyr Val His 1 5 10 <210> 17 <211> 17 <212> PRT <213> Artificial sequence <220> <223> DLL3#3 HCCDR2 <400> 17 Ile Ile Asn Pro Gly Gly Gly Thr Thr Ser Tyr Ala Gln Lys Phe Leu 1 5 10 15 Gly <210> 18 <211> 15 <212> PRT <213> Artificial sequence <220> <223> DLL3#3 HCCDR3 <400> 18 Gly Glu Ala Val Thr Gly Asn Tyr Phe Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 19 <211> 15 <212> PRT <213> Artificial sequence <220> <223> DLL3#4 LCCDR1 <400> 19 Arg Ala Ser Lys Ser Val Ser Ser Phe Gly Tyr Ser Phe Met His 1 5 10 15 <210> 20 <211> 7 <212> PRT <213> Artificial sequence <220> <223> DLL3#4 LCCDR2 <400> 20 Leu Ala Ser Asn Leu Glu Ser 1 5 <210> twenty one <211> 9 <212> PRT <213> Artificial sequence <220> <223> DLL3#4 LCCDR3 <400> twenty one Gln His Ser Arg Glu Leu Pro Trp Thr 1 5 <210> twenty two <211> 10 <212> PRT <213> Artificial sequence <220> <223> DLL3#4 HCCDR1 <400> twenty two Val Tyr Thr Phe Thr Ser Tyr Phe Met Tyr 1 5 10 <210> twenty three <211> 17 <212> PRT <213> Artificial sequence <220> <223> DLL3#4 HCCDR2 <400> twenty three Glu Ile Ser Pro Thr Asn Gly Asn Ser Asn Leu Asn Glu Arg Phe Lys 1 5 10 15 Asn <210> twenty four <211> 8 <212> PRT <213> Artificial sequence <220> <223> DLL3#4 HCCDR3 <400> twenty four Gly Gly Asp Gly Tyr Leu Asp Tyr 1 5 <210> 25 <211> 11 <212> PRT <213> Artificial sequence <220> <223> DLL3#5 LCCDR1 <400> 25 Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10 <210> 26 <211> 7 <212> PRT <213> Artificial sequence <220> <223> DLL3#5 LCCDR2 <400> 26 Asp Ala Ser Asn Leu Glu Thr 1 5 <210> 27 <211> 10 <212> PRT <213> Artificial sequence <220> <223> DLL3#5 LCCDR3 <400> 27 Gln Gln Tyr Asp Asn Leu Pro Thr Trp Thr 1 5 10 <210> 28 <211> 10 <212> PRT <213> Artificial sequence <220> <223> DLL3#5 HCCDR1 <400> 28 Gly Phe Thr Phe Thr Gly Tyr Tyr Ile His 1 5 10 <210> 29 <211> 17 <212> PRT <213> Artificial sequence <220> <223> DLL3#5 HCCDR2 <400> 29 Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 30 <211> 4 <212> PRT <213> Artificial sequence <220> <223> DLL3#5 HCCDR3 <400> 30 Gly Trp Asp Tyr 1 <210> 31 <211> 11 <212> PRT <213> Artificial sequence <220> <223> DLL3#6 LCCDR1 <400> 31 Arg Ala Ser Gln Asp Ile Ser Asn Tyr Phe Ala 1 5 10 <210> 32 <211> 7 <212> PRT <213> Artificial sequence <220> <223> DLL3#6 LCCDR2 <400> 32 Ala Ala Ser Thr Leu Gln Ser 1 5 <210> 33 <211> 9 <212> PRT <213> Artificial sequence <220> <223> DLL3#6 LCCDR3 <400> 33 Gln Gln Leu Asn Ser Tyr Pro Tyr Thr 1 5 <210> 34 <211> 10 <212> PRT <213> Artificial sequence <220> <223> DLL3#6 HCCDR1 <400> 34 Gly Gly Ser Ile Ser Ser Tyr Phe Trp Ser 1 5 10 <210> 35 <211> 16 <212> PRT <213> Artificial sequence <220> <223> DLL3#6 HCCDR2 <400> 35 Arg Ile Tyr Thr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Asn Ser 1 5 10 15 <210> 36 <211> 9 <212> PRT <213> Artificial sequence <220> <223> DLL3#6 HCCDR3 <400> 36 Arg Gly Asp Trp Gly Gly Phe Asp Ile 1 5 <210> 37 <211> 108 <212> PRT <213> Synthetic sequence <220> <223> DLL3#1 VL <400> 37 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 20 25 30 Phe Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Pro Leu 35 40 45 Ile Tyr Gly Ala Ser Thr Arg Ala Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Ala Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Leu Tyr Tyr Cys Gln Gln Tyr Gly Asp Ser Pro 85 90 95 Tyr Thr Phe Gly Gln Gly Thr Thr Leu Glu Ile Lys 100 105 <210> 38 <211> 121 <212> PRT <213> Synthetic sequence <220> <223> DLL3#1 VH <400> 38 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Asn Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Pro Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asp Pro Ser Val Gly Ser Lys Ser Tyr Ala Gln Lys Phe 50 55 60 Leu Gly Arg Val Thr Ile Ala Arg Asp Thr Ser Thr Ser Thr Val Phe 65 70 75 80 Leu Asp Leu Tyr Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95 Ala Arg Ala Gly Lys Arg Phe Gly Glu Ser Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 39 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> DLL3#2 VL <400> 39 Asp Ile Gln Met Thr Gln Ser Pro Ser Ala Met Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr 20 25 30 Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Val Pro Glu Pro Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Val Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Ser Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 40 <211> 124 <212> PRT <213> Synthetic Sequence <220> <223> DLL3#2 VH <400> 40 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Glu Ala Val Gly Gly Asn Tyr Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 41 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> DLL3#3 VL <400> 41 Asp Ile Gln Met Thr Gln Ser Pro Ser Ala Met Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr 20 25 30 Leu Val Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile 35 40 45 Tyr Ala Val Ser Ser Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asp Ser Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 42 <211> 124 <212> PRT <213> Artificial Sequence <220> <223> DLL3#3 VH <400> 42 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Val His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Val Ile Ile Asn Pro Gly Gly Gly Thr Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Leu Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr 65 70 75 80 Met Glu Leu Lys Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Glu Ala Val Thr Gly Asn Tyr Phe Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 43 <211> 111 <(212)> PRT <(213)> Artificial sequence <220> <(223)> DLL3#4 VL <400> 43 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Ser Phe 20 25 30 Gly Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Note: The tags <212> and <223> were enclosed in parentheses to avoid potential confusion with the format requirements. In a proper patent text context, they should be in the correct format as per the original standard.65 70 75 80 Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg 85 90 95 Glu Leu Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 44 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> DLL3#4 VH <400> 44 Gln Val Gln Leu Gln Gln Ser Gly Thr Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Val Tyr Thr Phe Thr Ser Tyr 20 25 30 Phe Met Tyr Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Ser Pro Thr Asn Gly Asn Ser Asn Leu Asn Glu Arg Phe 50 55 60 Lys Asn Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Gly Gly Asp Gly Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Thr 100 105 110 Leu Thr Val Ser Ser 115 <210> 45 <211> 108 <212> PRT <213> Artificial sequence <220> <223> DLL3#5 VL <400> 45 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Val Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Thr 85 90 95 Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 46 <211> 113 <212> PRT <213> Artificial sequence <220> <223> DLL3#5 VH <400> 46 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Gly Tyr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Ser Ser Ile Asn Thr Ala Phe 65 70 75 80 Met Glu Leu Ser Arg Leu Thr Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ala Gly Trp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110 Ser <210> 47 <211> 107 <212> PRT <213> Artificial sequence <220> <223> DLL3#6 VL <400> 47 Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Thr Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Phe Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Gly Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 48 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> DLL3#6 VH <400> 48 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Phe Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Thr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Asn 50 55 60 Ser Arg Leu Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Arg Gly Asp Trp Gly Gly Phe Asp Ile Trp Gly Gln Gly Thr Val 100 105 110 Val Thr Val Ser Ser 115 <210> 49 <211> 477 <212> PRT <213> artificial sequence <220> <223> DLL3#1 scFab <400> 49 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 20 25 30 Phe Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Pro Leu 35 40 45 Ile Tyr Gly Ala Ser Thr Arg Ala Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Ala Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Leu Tyr Tyr Cys Gln Gln Tyr Gly Asp Ser Pro 85 90 95 Tyr Thr Phe Gly Gln Gly Thr Thr Leu Glu Ile Lys Arg Thr Val Ala 100 105 110 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 145 150 155 160 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser 210 215 220 Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly 225 230 235 240 Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Val Gln 245 250 255 Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys 260 265 270 Val Ser Cys Lys Ala Ser Gly Asn Thr Phe Thr Asn Tyr Tyr Met His 275 280 285 Trp Val Arg Gln Ala Pro Gly Pro Gly Leu Glu Trp Met Gly Ile Ile 290 295 300 Asp Pro Ser Val Gly Ser Lys Ser Tyr Ala Gln Lys Phe Leu Gly Arg 305 310 315 320 Val Thr Ile Ala Arg Asp Thr Ser Thr Ser Thr Val Phe Leu Asp Leu 325 330 335 Tyr Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys Ala Arg Ala 340 345 350 Gly Lys Arg Phe Gly Glu Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 355 360 365 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 370 375 380 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 385 390 395 400 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 405 410 415 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 420 425 430 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 435 440 445 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 450 455 460 Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 465 470 475 <210> 50 <211> 479 <212> PRT <213> artificial sequence <220> <223> DLL3#2 scFab <400> 50 Asp Ile Gln Met Thr Gln Ser Pro Ser Ala Met Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr 20 25 30 Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Val Pro Glu Pro Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Val Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Ser Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser Ser 210 215 220 Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly Ser 225 230 235 240 Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Val Gln Leu 245 250 255 Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val 260 265 270 Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp 275 280 285 Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn 290 295 300 Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val 305 310 315 320 Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser 325 330 335 Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Glu 340 345 350 Ala Val Gly Gly Asn Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln 355 360 365 Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 370 375 380 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 385 390 395 400 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 405 410 415 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 420 425 430 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 435 440 445 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 450 455 460 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 465 470 475 <210> 51 <211> 479 <212> PRT <213> artificial sequence <220> <223> DLL3#3 scFab <400> 51 Asp Ile Gln Met Thr Gln Ser Pro Ser Ala Met Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr 20 25 30 Leu Val Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile 35 40 45 Tyr Ala Val Ser Ser Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asp Ser Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser Ser 210 215 220 Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly Ser 225 230 235 240 Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Val Gln Leu 245 250 255 Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val 260 265 270 Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Val His Trp 275 280 285 Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Val Ile Ile Asn 290 295 300 Pro Gly Gly Gly Thr Thr Ser Tyr Ala Gln Lys Phe Leu Gly Arg Val 305 310 315 320 Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr Met Glu Leu Lys 325 330 335 Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Glu 340 345 350 Ala Val Thr Gly Asn Tyr Phe Tyr Tyr Gly Met Asp Val Trp Gly Gln 355 360 365 Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 370 375 380 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 385 390 395 400 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 405 410 415 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 420 425 430 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 435 440 445 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 450 455 460 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 465 470 475 <210> 52 <211> 476 <212> PRT <213> Artificial Sequence <220> <223> DLL3#4 scFab <400> 52 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Ser Phe 20 25 30 Gly Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 65 70 75 80 Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg 85 90 95 Glu Leu Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 100 105 110 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 115 120 125 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 130 135 140 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 145 150 155 160 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 165 170 175 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 180 185 190 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 195 200 205 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu 210 215 220 Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys 225 230 235 240 Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser 245 250 255 Gln Val Gln Leu Gln Gln Ser Gly Thr Glu Leu Val Lys Pro Gly Ala 260 265 270 Ser Val Lys Leu Ser Cys Lys Ala Ser Val Tyr Thr Phe Thr Ser Tyr 275 280 285 Phe Met Tyr Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 290 295 300 Gly Glu Ile Ser Pro Thr Asn Gly Asn Ser Asn Leu Asn Glu Arg Phe 305 310 315 320 Lys Asn Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 325 330 335 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 340 345 350 Thr Arg Gly Gly Asp Gly Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Thr 355 360 365 Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 370 375 380 Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys 385 390 395 400 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 405 410 415 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 420 425 430 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 435 440 445 Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn 450 455 460 Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 465 470 475 <210> 53 <211> 469 <212> PRT <213> artificial sequence <220> <223> DLL3#5 scFab <400> 53 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Val Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Thr 85 90 95 Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala 100 105 110 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 145 150 155 160 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser 210 215 220 Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly 225 230 235 240 Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Val Gln 245 250 255 Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys 260 265 270 Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Gly Tyr Tyr Ile His 275 280 285 Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile 290 295 300 Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg 305 310 315 320 Val Thr Met Thr Arg Asp Ser Ser Ile Asn Thr Ala Phe Met Glu Leu 325 330 335 Ser Arg Leu Thr Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Ala Gly 340 345 350 Trp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser 355 360 365 Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr 370 375 380 Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro 385 390 395 400 Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val 405 410 415 His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser 420 425 430 Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile 435 440 445 Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val 450 455 460 Glu Pro Lys Ser Cys 465 <210> 54 <211> 472 <212> PRT <213> artificial sequence <220> <223> DLL3#6 scFab <400> 54 Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Thr Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Phe Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Gly Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser Ser 210 215 220 Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly Ser 225 230 235 240 Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Val Gln Leu 245 250 255 Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu 260 265 270 Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Phe Trp Ser Trp 275 280 285 Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr 290 295 300 Thr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Asn Ser Arg Leu Thr 305 310 315 320 Met Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser 325 330 335 Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Arg Gly Asp 340 345 350 Trp Gly Gly Phe Asp Ile Trp Gly Gln Gly Thr Val Val Thr Val Ser 355 360 365 Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser 370 375 380 Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp 385 390 395 400 Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr 405 410 415 Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr 420 425 430 Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln 435 440 445 Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp 450 455 460 Lys Arg Val Glu Pro Lys Ser Cys 465 470 <210> 55 <211> 14 <212> PRT <213> artificial sequence <220> <223> CD3#1 LCCDR1 <400> 55 Arg Ser Ser Thr Gly Ala Val Thr Thr Ser Asn Tyr Ala Asn 1 5 10 <210> 56 <211> 7 <212> PRT <213> artificial sequence <220> <223> CD3#1 LCCDR2 <400> 56 Gly Thr Asn Lys Arg Ala Pro 1 5 <210> 57 <211> 9 <212> PRT <213> Artificial sequence <220> <223> CD3#1 LCCDR3 <400> 57 Ala Leu Trp Tyr Ser Asn Leu Trp Val 1 5 <210> 58 <211> 10 <212> PRT <213> Artificial sequence <220> <223> CD3#1 HCCDR1 <400> 58 Gly Phe Thr Phe Asn Thr Tyr Ala Met Asn 1 5 10 <210> 59 <211> 19 <212> PRT <213> Artificial sequence <220> <223> CD3#1 HCCDR2 <400> 59 Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser 1 5 10 15 Val Lys Asp <210> 60 <211> 14 <212> PRT <213> Artificial sequence <220> <223> CD3#1 HCCDR3 <400> 60 His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe Ala Tyr 1 5 10 <210> 61 <211> 14 <212> PRT <213> Artificial sequence <220> <223> CD3#2 LCCDR1 <400> 61 Arg Ser Ser Thr Gly Ala Val Thr Thr Ser Asn Tyr Ala Asn 1 5 10 <210> 62 <211> 7 <212> PRT <213> Artificial sequence <220> <223> CD3#2 LCCDR2 <400> 62 Gly Thr Asn Lys Arg Ala Pro 1 5 <210> 63 <211> 9 <212> PRT <213> Artificial sequence <220> <223> CD3#2 LCCDR3 <400> 63 Ala Leu Trp Tyr Ser Asn Leu Trp Val 1 5 <210> 64 <211> 10 <212> PRT <213> Artificial sequence <220> <223> CD3#2 HCCDR1 <400> 64 Gly Phe Thr Phe Asn Thr Tyr Ala Met Asn 1 5 10 <210> 65 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> CD3#2 HCCDR2 <400> 65 Arg Ile Arg Ser Lys Tyr Ile Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser 1 5 10 15 Val Lys Asp <210> 66 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> CD3#2 HCCDR3 <400> 66 His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe Ala Tyr 1 5 10 <210> 67 <211> 109 <212> PRT <213> Artificial Sequence <220> <223> CD3#1 VL <400> 67 Glu Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser 20 25 30 Asn Tyr Ala Asn Trp Val Gln Glu Lys Pro Gly Gln Leu Pro Arg Gly 35 40 45 Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Trp Val Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Ala 65 70 75 80 Gln Pro Glu Asp Glu Ala Glu Tyr Phe Cys Ala Leu Trp Tyr Ser Asn 85 90 95 Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 68 <211> 125 <212> PRT <213> Artificial Sequence <220> <223> CD3#1 VH <400> 68 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala 115 120 125 <210> 69 <211> 109 <212> PRT <213> Artificial sequence <220> <223> CD3#2 VL <400> 69 Glu Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser 20 25 30 Asn Tyr Ala Asn Trp Val Gln Glu Lys Pro Gly Gln Leu Pro Arg Gly 35 40 45 Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Trp Val Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Ala 65 70 75 80 Gln Pro Glu Asp Glu Ala Glu Tyr Phe Cys Ala Leu Trp Tyr Ser Asn 85 90 95 Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 70 <211> 125 <212> PRT <213> Artificial sequence <220> <223> CD3#2 VH <400> 70 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Ile Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala 115 120 125 <210> 71 <211> 481 <212> PRT <213> Artificial sequence <220> <223> CD3#1 scFab <400> 71 Glu Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser 20 25 30 Asn Tyr Ala Asn Trp Val Gln Glu Lys Pro Gly Gln Leu Pro Arg Gly 35 40 45 Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Trp Val Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Ala 65 70 75 80 Gln Pro Glu Asp Glu Ala Glu Tyr Phe Cys Ala Leu Trp Tyr Ser Asn 85 90 95 Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Lys Val Ala Trp Lys Ala Asp Gly Ser Pro Val Asn Thr 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Ala Glu Cys Ser Gly Gly Gly Gly Ser Glu Gly Lys Ser 210 215 220 Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly 225 230 235 240 Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Glu Val Gln 245 250 255 Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys 260 265 270 Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr Ala Met Asn 275 280 285 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile 290 295 300 Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys 305 310 315 320 Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu 325 330 335 Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val 340 345 350 Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe Ala Tyr Trp 355 360 365 Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys Gly Pro 370 375 380 Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 385 390 395 400 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 405 410 415 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 420 425 430 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 435 440 445 Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn 450 455 460 His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser 465 470 475 480 Cys <210> 72 <211> 481 <212> PRT <213> Artificial Sequence <220> <223> CD3#2 scFab <400> 72 Glu Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser 20 25 30 Asn Tyr Ala Asn Trp Val Gln Glu Lys Pro Gly Gln Leu Pro Arg Gly 35 40 45 Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Trp Val Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Ala 65 70 75 80 Gln Pro Glu Asp Glu Ala Glu Tyr Phe Cys Ala Leu Trp Tyr Ser Asn 85 90 95 Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Lys Val Ala Trp Lys Ala Asp Gly Ser Pro Val Asn Thr 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Ala Glu Cys Ser Gly Gly Gly Gly Ser Glu Gly Lys Ser 210 215 220 Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly 225 230 235 240 Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Glu Val Gln 245 250 255 Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys 260 265 270 Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr Ala Met Asn 275 280 285 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile 290 295 300 Arg Ser Lys Tyr Ile Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys 305 310 315 320 Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu 325 330 335 Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val 340 345 350 Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe Ala Tyr Trp 355 360 365 Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys Gly Pro 370 375 380 Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 385 390 395 400 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 405 410 415 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 420 425 430 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 435 440 445 Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn 450 455 460 His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser 465 470 475 480 Cys <210> 73 <211> 703 <212> PRT <213> Artificial Sequence <220> <223> DLL3#1 Chain <400> 73 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 20 25 30 Phe Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Pro Leu 35 40 45 Ile Tyr Gly Ala Ser Thr Arg Ala Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Ala Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Leu Tyr Tyr Cys Gln Gln Tyr Gly Asp Ser Pro 85 90 95 Tyr Thr Phe Gly Gln Gly Thr Thr Leu Glu Ile Lys Arg Thr Val Ala 100 105 110 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 145 150 155 160 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser 210 215 220 Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly 225 230 235 240 Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Val Gln 245 250 255 Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys 260 265 270 Val Ser Cys Lys Ala Ser Gly Asn Thr Phe Thr Asn Tyr Tyr Met His 275 280 285 Trp Val Arg Gln Ala Pro Gly Pro Gly Leu Glu Trp Met Gly Ile Ile 290 295 300 Asp Pro Ser Val Gly Ser Lys Ser Tyr Ala Gln Lys Phe Leu Gly Arg 305 310 315 320 Val Thr Ile Ala Arg Asp Thr Ser Thr Ser Thr Val Phe Leu Asp Leu 325 330 335 Tyr Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys Ala Arg Ala 340 345 350 Gly Lys Arg Phe Gly Glu Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 355 360 365 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 370 375 380 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 385 390 395 400 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 405 410 415 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 420 425 430 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 435 440 445 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 450 455 460 Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr 465 470 475 480 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser 485 490 495 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 500 505 510 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 515 520 525 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 530 535 540 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 545 550 555 560 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 565 570 575 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 580 585 590 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 595 600 605 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Trp Cys 610 615 620 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 625 630 635 640 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 645 650 655 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 660 665 670 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 675 680 685 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 690 695 700 <210> 74 <211> 705 <212> PRT <213> Artificial Sequence <220> <223> DLL3#2 Chain <400> 74 Asp Ile Gln Met Thr Gln Ser Pro Ser Ala Met Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr 20 25 30 Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Val Pro Glu Pro Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Val Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Ser Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser Ser 210 215 220 Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly Ser 225 230 235 240 Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Val Gln Leu 245 250 255 Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val 260 265 270 Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp 275 280 285 Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn 290 295 300 Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val 305 310 315 320 Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser 325 330 335 Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Glu 340 345 350 Ala Val Gly Gly Asn Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln 355 360 365 Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 370 375 380 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 385 390 395 400 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 405 410 415 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 420 425 430 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 435 440 445 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 450 455 460 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 465 470 475 480 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly 485 490 495 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 500 505 510 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 515 520 525 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 530 535 540 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 545 550 555 560 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 565 570 575 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 580 585 590 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 595 600 605 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 610 615 620 Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 625 630 635 640 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 645 650 655 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 660 665 670 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 675 680 685 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 690 695 700 Gly 705 <210> 75 <211> 705 <212> PRT <213> Artificial Sequence <220> <223> DLL3 #3 Chain <400> 75 Asp Ile Gln Met Thr Gln Ser Pro Ser Ala Met Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr 20 25 30 Leu Val Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile 35 40 45 Tyr Ala Val Ser Ser Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asp Ser Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser Ser 210 215 220 Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly Ser 225 230 235 240 Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Val Gln Leu 245 250 255 Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val 260 265 270 Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Val His Trp 275 280 285 Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Val Ile Ile Asn 290 295 300 Pro Gly Gly Gly Thr Thr Ser Tyr Ala Gln Lys Phe Leu Gly Arg Val 305 310 315 320 Thr Met Thr Arg Asp Thr Ser Thr Asn Thr Val Tyr Met Glu Leu Lys 325 330 335 Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Glu 340 345 350 Ala Val Thr Gly Asn Tyr Phe Tyr Tyr Gly Met Asp Val Trp Gly Gln 355 360 365 Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 370 375 380 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 385 390 395 400 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 405 410 415 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 420 425 430 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 435 440 445 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 450 455 460 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 465 470 475 480 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly 485 490 495 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 500 505 510 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 515 520 525 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 530 535 540 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 545 550 555 560 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 565 570 575 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 580 585 590 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 595 600 605 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 610 615 620 Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 625 630 635 640 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 645 650 655 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 660 665 670 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 675 680 685 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 690 695 700 Gly 705 <210> 76 <211> 702 <212> PRT <213> Synthetic Sequence <220> <223> DLL3#4 Chain <400> 76 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Ser Phe 20 25 30 Gly Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 65 70 75 80 Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg 85 90 95 Glu Leu Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 100 105 110 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 115 120 125 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 130 135 140 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 145 150 155 160 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 165 170 175 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 180 185 190 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 195 200 205 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu 210 215 220 Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys 225 230 235 240 Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser 245 250 255 Gln Val Gln Leu Gln Gln Ser Gly Thr Glu Leu Val Lys Pro Gly Ala 260 265 270 Ser Val Lys Leu Ser Cys Lys Ala Ser Val Tyr Thr Phe Thr Ser Tyr 275 280 285 Phe Met Tyr Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile 290 295 300 Gly Glu Ile Ser Pro Thr Asn Gly Asn Ser Asn Leu Asn Glu Arg Phe 305 310 315 320 Lys Asn Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 325 330 335 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 340 345 350 Thr Arg Gly Gly Asp Gly Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Thr 355 360 365 Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 370 375 380 Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys 385 390 395 400 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 405 410 415 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 420 425 430 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 435 440 445 Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn 450 455 460 Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His 465 470 475 480 Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val 485 490 495 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 500 505 510 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 515 520 525 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 530 535 540 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 545 550 555 560 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 565 570 575 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 580 585 590 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 595 600 605 Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Trp Cys Leu 610 615 620 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 625 630 635 640 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 645 650 655 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 660 665 670 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 675 680 685 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 690 695 700 <210> 77 <211> 695 <212> PRT <213> Artificial Sequence <220> <223> DLL3 #5 Chain <400> 77 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Val Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Thr 85 90 95 Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala 100 105 110 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 145 150 155 160 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser 210 215 220 Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly 225 230 235 240 Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Val Gln 245 250 255 Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys 260 265 270 Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Gly Tyr Tyr Ile His 275 280 285 Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile 290 295 300 Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg 305 310 315 320 Val Thr Met Thr Arg Asp Ser Ser Ile Asn Thr Ala Phe Met Glu Leu 325 330 335 Ser Arg Leu Thr Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Ala Gly 340 345 350 Trp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser 355 360 365 Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr 370 375 380 Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro 385 390 395 400 Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val 405 410 415 His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser 420 425 430 Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile 435 440 445 Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val 450 455 460 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 465 470 475 480 Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 485 490 495 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 500 505 510 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 515 520 525 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 530 535 540 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 545 550 555 560 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 565 570 575 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 580 585 590 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr 595 600 605 Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser 610 615 620 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 625 630 635 640 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 645 650 655 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 660 665 670 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 675 680 685 Ser Leu Ser Leu Ser Pro Gly 690 695 <210> 78 <211> 698 <212> PRT <213> Artificial Sequence <220> <223> DLL3#6 Chain <400> 78 Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Thr Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Phe Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Gly Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser Ser 210 215 220 Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly Ser 225 230 235 240 Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Val Gln Leu 245 250 255 Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu 260 265 270 Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Phe Trp Ser Trp 275 280 285 Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr 290 295 300 Thr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Asn Ser Arg Leu Thr 305 310 315 320 Met Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser 325 330 335 Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Arg Gly Asp 340 345 350 Trp Gly Gly Phe Asp Ile Trp Gly Gln Gly Thr Val Val Thr Val Ser 355 360 365 Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser 370 375 380 Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp 385 390 395 400 Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr 405 410 415 Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr 420 425 430 Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln 435 440 445 Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp 450 455 460 Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro 465 470 475 480 Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro 485 490 495 Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 500 505 510 Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 515 520 525 Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 530 535 540 Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 545 550 555 560 Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 565 570 575 Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 580 585 590 Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu 595 600 605 Glu Met Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe 610 615 620 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 625 630 635 640 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 645 650 655 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 660 665 670 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 675 680 685 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 690 695 <210> 79 <211> 707 <212> PRT <213> artificial sequence <220> <223> CD3#1 chain <400> 79 Glu Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser 20 25 30 Asn Tyr Ala Asn Trp Val Gln Glu Lys Pro Gly Gln Leu Pro Arg Gly 35 40 45 Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Trp Val Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Ala 65 70 75 80 Gln Pro Glu Asp Glu Ala Glu Tyr Phe Cys Ala Leu Trp Tyr Ser Asn 85 90 95 Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Lys Val Ala Trp Lys Ala Asp Gly Ser Pro Val Asn Thr 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Ala Glu Cys Ser Gly Gly Gly Gly Ser Glu Gly Lys Ser 210 215 220 Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly 225 230 235 240 Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Glu Val Gln 245 250 255 Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys 260 265 270 Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr Ala Met Asn 275 280 285 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile 290 295 300 Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys 305 310 315 320 Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu 325 330 335 Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val 340 345 350 Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe Ala Tyr Trp 355 360 365 Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys Gly Pro 370 375 380 Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 385 390 395 400 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 405 410 415 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 420 425 430 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 435 440 445 Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn 450 455 460 His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser 465 470 475 480 Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala 485 490 495 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 500 505 510 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 515 520 525 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 530 535 540 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 545 550 555 560 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 565 570 575 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 580 585 590 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 595 600 605 Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val 610 615 620 Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 625 630 635 640 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 645 650 655 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr 660 665 670 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 675 680 685 Met His Glu Ala Leu His Asn Arg Phe Thr Gln Lys Ser Leu Ser Leu 690 695 700 Ser Pro Gly 705 <210> 80 <211> 707 <212> PRT <213> Artificial Sequence <220> <223> CD3 #2 Chain <400> 80 Glu Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser 20 25 30 Asn Tyr Ala Asn Trp Val Gln Glu Lys Pro Gly Gln Leu Pro Arg Gly 35 40 45 Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Trp Val Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Ala 65 70 75 80 Gln Pro Glu Asp Glu Ala Glu Tyr Phe Cys Ala Leu Trp Tyr Ser Asn 85 90 95 Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Lys Val Ala Trp Lys Ala Asp Gly Ser Pro Val Asn Thr 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Ala Glu Cys Ser Gly Gly Gly Gly Ser Glu Gly Lys Ser 210 215 220 Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly 225 230 235 240 Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Glu Val Gln 245 250 255 Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys 260 265 270 Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr Ala Met Asn 275 280 285 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile 290 295 300 Arg Ser Lys Tyr Ile Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys 305 310 315 320 Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu 325 330 335 Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val 340 345 350 Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe Ala Tyr Trp 355 360 365 Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys Gly Pro 370 375 380 Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 385 390 395 400 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 405 410 415 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 420 425 430 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 435 440 445 Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn 450 455 460 His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser 465 470 475 480 Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala 485 490 495 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 500 505 510 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 515 520 525 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 530 535 540 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 545 550 555 560 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 565 570 575 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 580 585 590 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 595 600 605 Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val 610 615 620 Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 625 630 635 640 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 645 650 655 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr 660 665 670 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 675 680 685 Met His Glu Ala Leu His Asn Arg Phe Thr Gln Lys Ser Leu Ser Leu 690 695 700 Ser Pro Gly 705 <210> 81 <211> 226 <212> PRT <213> Artificial sequence <220> <223> Fc region* (IgG1) <400> 81 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 130 135 140 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly 225 <210> 82 <211> 226 <212> PRT <213> Artificial Sequence <220> <223> Fcknob domain (IgG1,LALA) <400> 82 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 130 135 140 Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly 225 <210> 83 <211> 226 <212> PRT <213> Artificial sequence <220> <223> Fchole domain (IgG1,RF / LALA) <400> 83 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly 1 5 10 15 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 20 25 30 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 45 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 50 55 60 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 65 70 75 80 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 85 90 95 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 100 105 110 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 115 120 125 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 130 135 140 Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 155 160 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 165 170 175 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val 180 185 190 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 195 200 205 His Glu Ala Leu His Asn Arg Phe Thr Gln Lys Ser Leu Ser Leu Ser 210 215 220 Pro Gly 225 <210> 84 <211> 228 <212> PRT <213> Artificial sequence <220> <223> Fc region (IgG4Pro) <400> 84 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu 180 185 190 Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser 195 200 205 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220 Leu Ser Leu Gly 225 <210> 85 <211> 228 <212> PRT <213> Artificial sequence <220> <223> Fcknob domain (IgG4Pro) <400> 85 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu 180 185 190 Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser 195 200 205 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220 Leu Ser Leu Gly 225 <210> 86 <211> 228 <212> PRT <213> Artificial sequence <220> <223> Fchole domain (IgG4Pro, RF) <400> 86 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Arg Leu 180 185 190 Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser 195 200 205 Val Met His Glu Ala Leu His Asn Arg Phe Thr Gln Lys Ser Leu Ser 210 215 220 Leu Ser Leu Gly 225 <210> 87 <211> 107 <212> PRT <213> Artificial sequence <220> <223> constantregionofakappalightchain <400> 87 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 1 5 10 15 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 25 30 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 35 40 45 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 50 55 60 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 65 70 75 80 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 85 90 95 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 105 <210> 88 <211> 106 <212> PRT <213> Artificial sequence <220> <223> constant region of the lambda light chain <400> 88 Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser 1 5 10 15 Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp 20 25 30 Phe Tyr Pro Gly Ala Val Lys Val Ala Trp Lys Ala Asp Gly Ser Pro 35 40 45 Val Asn Thr Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn 50 55 60 Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys 65 70 75 80 Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val 85 90 95 Glu Lys Thr Val Ala Pro Ala Glu Cys Ser 100 105 <210> 89 <211> 38 <212> PRT <213> Artificial Sequence <220> <223> Linker <400> 89 Gly Gly Gly Gly Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser 1 5 10 15 Lys Ser Thr Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser 20 25 30 Thr Gly Gly Gly Gly Ser 35 <210> 90 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Linker <400> 90 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Ser Gly Gly Ser 1 5 10 15 Gly Gly Gly Gly Gly Ser 20 <210> 91 <211> 26 <212> PRT <213> Artificial Sequence <220> <223> Linker <400> 91 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1 5 10 15 Gly Gly Gly Ser Gly Gly Gly Gly Gly Ser 20 25 <210> 92 <211> 30 <212> PRT <213> Artificial Sequence <220> <223> Linker <400> 92 Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly 1 5 10 15 Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Ser 20 25 30 <210> 93 <211> 34 <212> PRT <213> Artificial sequence <220> <223> Adaptor <400> 93 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 1 5 10 15 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 20 25 30 Gly Ser <210> 94 <211> 38 <212> PRT <213> Artificial sequence <220> <223> Adaptor <400> 94 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 1 5 10 15 Gly Ser Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 20 25 30 Gly Gly Gly Gly Gly Ser 35 <210> 95 <211> 42 <212> PRT <213> Artificial sequence <220> <223> Adaptor <400> 95 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 1 5 10 15 Gly Ser Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly 20 25 30 Ser Gly Gly Gly Ser Gly Gly Gly Gly Ser 35 40 <210> 96 <211> 14 <212> PRT <213> Artificial sequence <220> <223> CD3#3 LCCDR1 <400> 96 Arg Ser Ser Thr Gly Ala Val Thr Thr Ser Asn Tyr Ala Asn 1 5 10 <210> 97 <211> 7 <212> PRT <213> Artificial sequence <220> <223> CD3#3 LCCDR2 <400> 97 Gly Thr Asn Lys Arg Ala Pro 1 5 <210> 98 <211> 9 <212> PRT <213> Artificial sequence <220> <223> CD3#3 LCCDR3 <400> 98 Ala Leu Trp Tyr Ser Asn Leu Trp Val 1 5 <210> 99 <211> 10 <212> PRT <213> Artificial sequence <220> <223> CD3#3 HCCDR1 <400> 99 Gly Phe Thr Phe Asn Thr Tyr Ala Met Asn 1 5 10 <210> 100 <211> 19 <212> PRT <213> Synthetic Sequence <220> <223> CD3#3 HCCDR2 <400> 100 Arg Ile Arg Ser Lys Tyr Ala Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser 1 5 10 15 Val Lys Asp <210> 101 <211> 14 <212> PRT <213> Synthetic Sequence <220> <223> CD3#3 HCCDR3 <400> 101 His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe Ala Tyr 1 5 10 <210> 102 <211> 109 <212> PRT <213> Synthetic Sequence <220> <223> CD3#3 VL <400> 102 Glu Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser 20 25 30 Asn Tyr Ala Asn Trp Val Gln Glu Lys Pro Gly Gln Leu Pro Arg Gly 35 40 45 Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Trp Val Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Ala 65 70 75 80 Gln Pro Glu Asp Glu Ala Glu Tyr Phe Cys Ala Leu Trp Tyr Ser Asn 85 90 95 Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 103 <211> 125 <212> PRT <213> Synthetic Sequence <220> <223> CD3#3 HL <400> 103 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Tyr Ala Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Ala Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala 115 120 125 <210> 104 <211> 481 <212> PRT <213> Synthetic Sequence <220> <223> CD3#3 scFab <400> 104 Glu Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser 20 25 30 Asn Tyr Ala Asn Trp Val Gln Glu Lys Pro Gly Gln Leu Pro Arg Gly 35 40 45 Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Trp Val Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Ala 65 70 75 80 Gln Pro Glu Asp Glu Ala Glu Tyr Phe Cys Ala Leu Trp Tyr Ser Asn 85 90 95 Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Lys Val Ala Trp Lys Ala Asp Gly Ser Pro Val Asn Thr 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Ala Glu Cys Ser Gly Gly Gly Gly Ser Glu Gly Lys Ser 210 215 220 Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly 225 230 235 240 Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Glu Val Gln 245 250 255 Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys 260 265 270 Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr Ala Met Asn 275 280 285 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile 290 295 300 Arg Ser Lys Tyr Ala Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys 305 310 315 320 Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu 325 330 335 Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val 340 345 350 Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe Ala Tyr Trp 355 360 365 Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys Gly Pro 370 375 380 Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 385 390 395 400 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 405 410 415 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 420 425 430 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 435 440 445 Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn 450 455 460 His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser 465 470 475 480 Cys <210> 105 <211> 707 <212> PRT <213> Artificial sequence <220> <223> CD3#3 chain <400> 105 Glu Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser 20 25 30 Asn Tyr Ala Asn Trp Val Gln Glu Lys Pro Gly Gln Leu Pro Arg Gly 35 40 45 Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Trp Val Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Ala 65 70 75 80 Gln Pro Glu Asp Glu Ala Glu Tyr Phe Cys Ala Leu Trp Tyr Ser Asn 85 90 95 Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro 100 105 110 Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu 115 120 125 Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro 130 135 140 Gly Ala Val Lys Val Ala Trp Lys Ala Asp Gly Ser Pro Val Asn Thr 145 150 155 160 Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala 165 170 175 Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg 180 185 190 Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr 195 200 205 Val Ala Pro Ala Glu Cys Ser Gly Gly Gly Gly Ser Glu Gly Lys Ser 210 215 220 Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly 225 230 235 240 Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Glu Val Gln 245 250 255 Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys 260 265 270 Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr Ala Met Asn 275 280 285 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile 290 295 300 Arg Ser Lys Tyr Ala Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys 305 310 315 320 Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu 325 330 335 Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Val 340 345 350 Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe Ala Tyr Trp 355 360 365 Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys Gly Pro 370 375 380 Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr 385 390 395 400 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 405 410 415 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 420 425 430 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 435 440 445 Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn 450 455 460 His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser 465 470 475 480 Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala 485 490 495 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 500 505 510 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 515 520 525 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 530 535 540 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 545 550 555 560 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 565 570 575 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 580 585 590 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 595 600 605 Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val 610 615 620 Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 625 630 635 640 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 645 650 655 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr 660 665 670 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 675 680 685 Met His Glu Ala Leu His Asn Arg Phe Thr Gln Lys Ser Leu Ser Leu 690 695 700 Ser Pro Gly 705 <210> 106 <211> 476 <212> PRT <213> Artificial Sequence <220> <223> HuDLL3(ECD)-His <400> 106 Ala Gly Val Phe Glu Leu Gln Ile His Ser Phe Gly Pro Gly Pro Gly 1 5 10 15 Pro Gly Ala Pro Arg Ser Pro Cys Ser Ala Arg Leu Pro Cys Arg Leu 20 25 30 Phe Phe Arg Val Cys Leu Lys Pro Gly Leu Ser Glu Glu Ala Ala Glu 35 40 45 Ser Pro Cys Ala Leu Gly Ala Ala Leu Ser Ala Arg Gly Pro Val Tyr 50 55 60 Thr Glu Gln Pro Gly Ala Pro Ala Pro Asp Leu Pro Leu Pro Asp Gly 65 70 75 80 Leu Leu Gln Val Pro Phe Arg Asp Ala Trp Pro Gly Thr Phe Ser Phe 85 90 95 Ile Ile Glu Thr Trp Arg Glu Glu Leu Gly Asp Gln Ile Gly Gly Pro 100 105 110 Ala Trp Ser Leu Leu Ala Arg Val Ala Gly Arg Arg Arg Leu Ala Ala 115 120 125 Gly Gly Pro Trp Ala Arg Asp Ile Gln Arg Ala Gly Ala Trp Glu Leu 130 135 140 Arg Phe Ser Tyr Arg Ala Arg Cys Glu Pro Pro Ala Val Gly Thr Ala 145 150 155 160 Cys Thr Arg Leu Cys Arg Pro Arg Ser Ala Pro Ser Arg Cys Gly Pro 165 170 175 Gly Leu Arg Pro Cys Ala Pro Leu Glu Asp Glu Cys Glu Ala Pro Leu 180 185 190 Val Cys Arg Ala Gly Cys Ser Pro Glu His Gly Phe Cys Glu Gln Pro 195 200 205 Gly Glu Cys Arg Cys Leu Glu Gly Trp Thr Gly Pro Leu Cys Thr Val 210 215 220 Pro Val Ser Thr Ser Ser Cys Leu Ser Pro Arg Gly Pro Ser Ser Ala 225 230 235 240 Thr Thr Gly Cys Leu Val Pro Gly Pro Gly Pro Cys Asp Gly Asn Pro 245 250 255 Cys Ala Asn Gly Gly Ser Cys Ser Glu Thr Pro Arg Ser Phe Glu Cys 260 265 270 Thr Cys Pro Arg Gly Phe Tyr Gly Leu Arg Cys Glu Val Ser Gly Val 275 280 285 Thr Cys Ala Asp Gly Pro Cys Phe Asn Gly Gly Leu Cys Val Gly Gly 290 295 300 Ala Asp Pro Asp Ser Ala Tyr Ile Cys His Cys Pro Pro Gly Phe Gln 305 310 315 320 Gly Ser Asn Cys Glu Lys Arg Val Asp Arg Cys Ser Leu Gln Pro Cys 325 330 335 Arg Asn Gly Gly Leu Cys Leu Asp Leu Gly His Ala Leu Arg Cys Arg 340 345 350 Cys Arg Ala Gly Phe Ala Gly Pro Arg Cys Glu His Asp Leu Asp Asp 355 360 365 Cys Ala Gly Arg Ala Cys Ala Asn Gly Gly Thr Cys Val Glu Gly Gly 370 375 380 Gly Ala His Arg Cys Ser Cys Ala Leu Gly Phe Gly Gly Arg Asp Cys 385 390 395 400 Arg Glu Arg Ala Asp Pro Cys Ala Ala Arg Pro Cys Ala His Gly Gly 405 410 415 Arg Cys Tyr Ala His Phe Ser Gly Leu Val Cys Ala Cys Ala Pro Gly 420 425 430 Tyr Met Gly Ala Arg Cys Glu Phe Pro Val His Pro Asp Gly Ala Ser 435 440 445 Ala Leu Pro Ala Ala Pro Pro Gly Leu Arg Pro Gly Asp Pro Gln Arg 450 455 460 Tyr Leu Ala Gly Ser Ala His His His His His His 465 470 475 <210> 107 <211> 476 <212> PRT <213> Synthetic <220> <223> CynoDLL3(ECD)-His <400> 107 Ala Gly Val Phe Glu Leu Gln Ile His Ser Phe Gly Pro Gly Pro Gly 1 5 10 15 Pro Gly Ala Pro Arg Ser Pro Cys Ser Ala Arg Gly Pro Cys Arg Leu 20 25 30 Phe Phe Arg Val Cys Leu Lys Pro Gly Leu Ser Glu Glu Ala Ala Glu 35 40 45 Note: In the translation of , "Synthetic" is used instead of "Artificial" as it is more appropriate in the context of patent texts to refer to a synthetic sequence. Also, "PRT" remains as it is since it's likely an abbreviation specific to the field and there's no clear indication for a more descriptive translation.Ser Pro Cys Ala Leu Gly Ala Ala Leu Ser Ala Arg Gly Pro Val Tyr 50 55 60 Thr Glu Gln Pro Glu Ala Pro Ala Pro Asp Leu Pro Leu Pro Asn Gly 65 70 75 80 Leu Leu Gln Val Pro Phe Arg Asp Ala Trp Pro Gly Thr Phe Ser Leu 85 90 95 Ile Ile Glu Thr Trp Arg Glu Glu Leu Gly Asp Gln Ile Gly Gly Pro 100 105 110 Ala Trp Ser Leu Leu Ala Arg Val Thr Arg Arg Arg Arg Leu Ala Ala 115 120 125 Gly Gly Pro Trp Ala Arg Asp Ile Gln Arg Ala Gly Ala Trp Glu Leu 130 135 140 Arg Phe Ser Tyr Arg Ala Arg Cys Glu Leu Pro Ala Val Gly Thr Ala 145 150 155 160 Cys Thr Arg Leu Cys Arg Pro Arg Ser Ala Pro Ser Arg Cys Gly Pro 165 170 175 Gly Leu Arg Pro Cys Ala Pro Leu Glu Asp Glu Cys Glu Ala Pro Pro 180 185 190 Val Cys Arg Ala Gly Cys Ser Leu Glu His Gly Phe Cys Glu Gln Pro 195 200 205 Gly Glu Cys Arg Cys Leu Glu Gly Trp Thr Gly Pro Leu Cys Met Val 210 215 220 Pro Val Ser Thr Ser Ser Cys Leu Gly Leu Arg Gly Pro Ser Ser Thr 225 230 235 240 Thr Thr Gly Cys Leu Val Pro Gly Pro Gly Pro Cys Asp Gly Asn Pro 245 250 255 Cys Ala Asn Gly Gly Ser Cys Ser Glu Thr Pro Gly Ser Phe Glu Cys 260 265 270 Thr Cys Pro Arg Gly Phe Tyr Gly Leu Arg Cys Glu Val Ser Gly Val 275 280 285 Thr Cys Ala Asp Gly Pro Cys Phe Asn Gly Gly Leu Cys Val Gly Gly 290 295 300 Ala Asp Pro Asp Ser Ala Tyr Ile Cys His Cys Pro Pro Gly Phe Gln 305 310 315 320 Gly Ser Asn Cys Glu Lys Arg Val Asp Arg Cys Ser Leu Gln Pro Cys 325 330 335 Arg Asn Gly Gly Leu Cys Leu Asp Leu Gly His Ala Leu Arg Cys Arg 340 345 350 Cys Arg Ala Gly Phe Ala Gly Pro Arg Cys Glu His Asp Leu Asp Asp 355 360 365 Cys Ala Gly Arg Ala Cys Ala Asn Gly Gly Thr Cys Val Glu Gly Gly 370 375 380 Gly Ala His Arg Cys Ser Cys Ala Leu Gly Phe Gly Gly Arg Asn Cys 385 390 395 400 Arg Glu Arg Ala Asp Pro Cys Ala Ala Arg Pro Cys Ala His Gly Gly 405 410 415 Arg Cys Tyr Ala His Phe Ser Gly Leu Val Cys Ala Cys Ala Pro Gly 420 425 430 Tyr Met Gly Ala Arg Cys Glu Phe Pro Val His Pro Asp Gly Val Ser 435 440 445 Ala Leu Pro Ala Ala Pro Pro Gly Leu Arg Pro Gly Asp Pro Gln Arg 450 455 460 Tyr Leu Ala Gly Ser Ala His His His His His His 465 470 475 <210> 108 <211> 487 <212> PRT <213> Artificial Sequence <220> <223> HuCD3E+G-HuFc-His <400> 108 Gln Asp Gly Asn Glu Glu Met Gly Gly Ile Thr Gln Thr Pro Tyr Lys 1 5 10 15 Val Ser Ile Ser Gly Thr Thr Val Ile Leu Thr Cys Pro Gln Tyr Pro 20 25 30 Gly Ser Glu Ile Leu Trp Gln His Asn Asp Lys Asn Ile Gly Gly Asp 35 40 45 Glu Asp Asp Lys Asn Ile Gly Ser Asp Glu Asp His Leu Ser Leu Lys 50 55 60 Glu Phe Ser Glu Leu Glu Gln Ser Gly Tyr Tyr Val Cys Tyr Pro Arg 65 70 75 80 Gly Ser Lys Pro Glu Asp Ala Asn Phe Tyr Leu Tyr Leu Arg Ala Arg 85 90 95 Val Cys Glu Asn Cys Met Glu Met Asp Gly Gly Gly Ser Gly Gly Gly 100 105 110 Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 115 120 125 Ser Gly Gly Gln Ser Ile Lys Gly Asn His Leu Val Lys Val Tyr Asp 130 135 140 Tyr Gln Glu Asp Gly Ser Val Leu Leu Thr Cys Asp Ala Glu Ala Lys 145 150 155 160 Asn Ile Thr Trp Phe Lys Asp Gly Lys Met Ile Gly Phe Leu Thr Glu 165 170 175 Asp Lys Lys Lys Trp Asn Leu Gly Ser Asn Ala Lys Asp Pro Arg Gly 180 185 190 Met Tyr Gln Cys Lys Gly Ser Gln Asn Lys Ser Lys Pro Leu Gln Val 195 200 205 Tyr Tyr Arg Met Cys Gln Asn Cys Ile Glu Leu Asn Ala Ala Thr Ile 210 215 220 Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser 225 230 235 240 Gly Gly Ser Gly Gly Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 245 250 255 Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 260 265 270 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 275 280 285 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 290 295 300 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 305 310 315 320 Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 325 330 335 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 340 345 350 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 355 360 365 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 370 375 380 Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 385 390 395 400 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 405 410 415 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 420 425 430 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 435 440 445 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 450 455 460 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Ala Gly Ser 465 470 475 480 Ala His His His His His His 485 <210> 109 <211> 477 <212> PRT <213> Artificial Sequence <220> <223> CynoCD3E+G-Fc-His <400> 109 Gln Asp Gly Asn Glu Glu Met Gly Ser Ile Thr Gln Thr Pro Tyr Gln 1 5 10 15 Val Ser Ile Ser Gly Thr Thr Val Ile Leu Thr Cys Ser Gln His Leu 20 25 30 Gly Ser Glu Ala Gln Trp Gln His Asn Gly Lys Asn Lys Gly Asp Ser 35 40 45 Gly Asp Gln Leu Phe Leu Pro Glu Phe Ser Glu Met Glu Gln Ser Gly 50 55 60 Tyr Tyr Val Cys Tyr Pro Arg Gly Ser Asn Pro Glu Asp Ala Ser His 65 70 75 80 His Leu Tyr Leu Lys Ala Arg Val Cys Glu Asn Cys Met Glu Met Asp 85 90 95 Val Met Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 100 105 110 Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gln Ser Phe Glu 115 120 125 Glu Asn Arg Lys Leu Asn Val Tyr Asn Gln Glu Asp Gly Ser Val Leu 130 135 140 Leu Thr Cys His Val Lys Asn Thr Asn Ile Thr Trp Phe Lys Glu Gly 145 150 155 160 Lys Met Ile Asp Ile Leu Thr Ala His Lys Asn Lys Trp Asn Leu Gly 165 170 175 Ser Asn Thr Lys Asp Pro Arg Gly Val Tyr Gln Cys Lys Gly Ser Lys 180 185 190 Asp Lys Ser Lys Thr Leu Gln Val Tyr Tyr Arg Met Cys Gln Asn Cys 195 200 205 Ile Glu Leu Asn Ala Ala Thr Gly Gly Ser Gly Gly Ser Gly Gly Ser 210 215 220 Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Glu Pro Lys Ser Cys 225 230 235 240 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 245 250 255 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 260 265 270 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 275 280 285 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 290 295 300 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 305 310 315 320 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 325 330 335 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 340 345 350 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 355 360 365 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 370 375 380 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 385 390 395 400 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 405 410 415 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 420 425 430 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 435 440 445 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 450 455 460 Pro Gly Lys Ala Gly Ser Ala His His His His His His 465 470 475 <210> 110 <211> 626 <212> PRT <213> Artificial sequence <220> <223> FLAG-tagged full-length human DLL3 <400> 110 Met Val Ser Pro Arg Met Ser Gly Leu Leu Ser Gln Thr Val Ile Leu 1 5 10 15 Ala Leu Ile Phe Leu Pro Gln Thr Arg Pro Asp Tyr Lys Asp Asp Asp 20 25 30 Asp Lys Ala Gly Val Phe Glu Leu Gln Ile His Ser Phe Gly Pro Gly 35 40 45 Pro Gly Pro Gly Ala Pro Arg Ser Pro Cys Ser Ala Arg Leu Pro Cys 50 55 60 Arg Leu Phe Phe Arg Val Cys Leu Lys Pro Gly Leu Ser Glu Glu Ala 65 70 75 80 Ala Glu Ser Pro Cys Ala Leu Gly Ala Ala Leu Ser Ala Arg Gly Pro 85 90 95 Val Tyr Thr Glu Gln Pro Gly Ala Pro Ala Pro Asp Leu Pro Leu Pro 100 105 110 Asp Gly Leu Leu Gln Val Pro Phe Arg Asp Ala Trp Pro Gly Thr Phe 115 120 125 Ser Phe Ile Ile Glu Thr Trp Arg Glu Glu Leu Gly Asp Gln Ile Gly 130 135 140 Gly Pro Ala Trp Ser Leu Leu Ala Arg Val Ala Gly Arg Arg Arg Leu 145 150 155 160 Ala Ala Gly Gly Pro Trp Ala Arg Asp Ile Gln Arg Ala Gly Ala Trp 165 170 175 Glu Leu Arg Phe Ser Tyr Arg Ala Arg Cys Glu Pro Pro Ala Val Gly 180 185 190 Thr Ala Cys Thr Arg Leu Cys Arg Pro Arg Ser Ala Pro Ser Arg Cys 195 200 205 Gly Pro Gly Leu Arg Pro Cys Ala Pro Leu Glu Asp Glu Cys Glu Ala 210 215 220 Pro Leu Val Cys Arg Ala Gly Cys Ser Pro Glu His Gly Phe Cys Glu 225 230 235 240 Gln Pro Gly Glu Cys Arg Cys Leu Glu Gly Trp Thr Gly Pro Leu Cys 245 250 255 Thr Val Pro Val Ser Thr Ser Ser Cys Leu Ser Pro Arg Gly Pro Ser 260 265 270 Ser Ala Thr Thr Gly Cys Leu Val Pro Gly Pro Gly Pro Cys Asp Gly 275 280 285 Asn Pro Cys Ala Asn Gly Gly Ser Cys Ser Glu Thr Pro Arg Ser Phe 290 295 300 Glu Cys Thr Cys Pro Arg Gly Phe Tyr Gly Leu Arg Cys Glu Val Ser 305 310 315 320 Gly Val Thr Cys Ala Asp Gly Pro Cys Phe Asn Gly Gly Leu Cys Val 325 330 335 Gly Gly Ala Asp Pro Asp Ser Ala Tyr Ile Cys His Cys Pro Pro Gly 340 345 350 Phe Gln Gly Ser Asn Cys Glu Lys Arg Val Asp Arg Cys Ser Leu Gln 355 360 365 Pro Cys Arg Asn Gly Gly Leu Cys Leu Asp Leu Gly His Ala Leu Arg 370 375 380 Cys Arg Cys Arg Ala Gly Phe Ala Gly Pro Arg Cys Glu His Asp Leu 385 390 395 400 Asp Asp Cys Ala Gly Arg Ala Cys Ala Asn Gly Gly Thr Cys Val Glu 405 410 415 Gly Gly Gly Ala His Arg Cys Ser Cys Ala Leu Gly Phe Gly Gly Arg 420 425 430 Asp Cys Arg Glu Arg Ala Asp Pro Cys Ala Ala Arg Pro Cys Ala His 435 440 445 Gly Gly Arg Cys Tyr Ala His Phe Ser Gly Leu Val Cys Ala Cys Ala 450 455 460 Pro Gly Tyr Met Gly Ala Arg Cys Glu Phe Pro Val His Pro Asp Gly 465 470 475 480 Ala Ser Ala Leu Pro Ala Ala Pro Pro Gly Leu Arg Pro Gly Asp Pro 485 490 495 Gln Arg Tyr Leu Leu Pro Pro Ala Leu Gly Leu Leu Val Ala Ala Gly 500 505 510 Val Ala Gly Ala Ala Leu Leu Leu Val His Val Arg Arg Arg Gly His 515 520 525 Ser Gln Asp Ala Gly Ser Arg Leu Leu Ala Gly Thr Pro Glu Pro Ser 530 535 540 Val His Ala Leu Pro Asp Ala Leu Asn Asn Leu Arg Thr Gln Glu Gly 545 550 555 560 Ser Gly Asp Gly Pro Ser Ser Ser Val Asp Trp Asn Arg Pro Glu Asp 565 570 575 Val Asp Pro Gln Gly Ile Tyr Val Ile Ser Ala Pro Ser Ile Tyr Ala 580 585 590 Arg Glu Val Ala Thr Pro Leu Phe Pro Pro Leu His Thr Gly Arg Ala 595 600 605 Gly Gln Arg Gln His Leu Leu Phe Pro Tyr Pro Ser Ser Ile Leu Ser 610 615 620 Val Lys 625 <210> 111 <211> 626 <212> PRT <213> Artificial Sequence <220> <223> FLAG-tagged cyno DLL3 full length <400> 111 Met Val Ser Pro Arg Met Ser Arg Leu Leu Ser Gln Thr Val Ile Leu 1 5 10 15 Ala Leu Ile Phe Ile Pro Gln Ala Arg Pro Asp Tyr Lys Asp Asp Asp 20 25 30 Asp Lys Ala Gly Val Phe Glu Leu Gln Ile His Ser Phe Gly Pro Gly 35 40 45 Pro Gly Pro Gly Ala Pro Arg Ser Pro Cys Ser Ala Arg Gly Pro Cys 50 55 60 Arg Leu Phe Phe Arg Val Cys Leu Lys Pro Gly Leu Ser Glu Glu Ala 65 70 75 80 Ala Glu Ser Pro Cys Ala Leu Gly Ala Ala Leu Ser Ala Arg Gly Pro 85 90 95 Val Tyr Thr Glu Gln Pro Glu Ala Pro Ala Pro Asp Leu Pro Leu Pro 100 105 110 Asn Gly Leu Leu Gln Val Pro Phe Arg Asp Ala Trp Pro Gly Thr Phe 115 120 125 Ser Leu Ile Ile Glu Thr Trp Arg Glu Glu Leu Gly Asp Gln Ile Gly 130 135 140 Gly Pro Ala Trp Ser Leu Leu Ala Arg Val Thr Arg Arg Arg Arg Leu 145 150 155 160 Ala Ala Gly Gly Pro Trp Ala Arg Asp Ile Gln Arg Ala Gly Ala Trp 165 170 175 Glu Leu Arg Phe Ser Tyr Arg Ala Arg Cys Glu Leu Pro Ala Val Gly 180 185 190 Thr Ala Cys Thr Arg Leu Cys Arg Pro Arg Ser Ala Pro Ser Arg Cys 195 200 205 Gly Pro Gly Leu Arg Pro Cys Ala Pro Leu Glu Asp Glu Cys Glu Ala 210 215 220 Pro Pro Val Cys Arg Ala Gly Cys Ser Leu Glu His Gly Phe Cys Glu 225 230 235 240 Gln Pro Gly Glu Cys Arg Cys Leu Glu Gly Trp Thr Gly Pro Leu Cys 245 250 255 Met Val Pro Val Ser Thr Ser Ser Cys Leu Gly Leu Arg Gly Pro Ser 260 265 270 Ser Thr Thr Thr Gly Cys Leu Val Pro Gly Pro Gly Pro Cys Asp Gly 275 280 285 Asn Pro Cys Ala Asn Gly Gly Ser Cys Ser Glu Thr Pro Gly Ser Phe 290 295 300 Glu Cys Thr Cys Pro Arg Gly Phe Tyr Gly Leu Arg Cys Glu Val Ser 305 310 315 320 Gly Val Thr Cys Ala Asp Gly Pro Cys Phe Asn Gly Gly Leu Cys Val 325 330 335 Gly Gly Ala Asp Pro Asp Ser Ala Tyr Ile Cys His Cys Pro Pro Gly 340 345 350 Phe Gln Gly Ser Asn Cys Glu Lys Arg Val Asp Arg Cys Ser Leu Gln 355 360 365 Pro Cys Arg Asn Gly Gly Leu Cys Leu Asp Leu Gly His Ala Leu Arg 370 375 380 Cys Arg Cys Arg Ala Gly Phe Ala Gly Pro Arg Cys Glu His Asp Leu 385 390 395 400 Asp Asp Cys Ala Gly Arg Ala Cys Ala Asn Gly Gly Thr Cys Val Glu 405 410 415 Gly Gly Gly Ala His Arg Cys Ser Cys Ala Leu Gly Phe Gly Gly Arg 420 425 430 Asn Cys Arg Glu Arg Ala Asp Pro Cys Ala Ala Arg Pro Cys Ala His 435 440 445 Gly Gly Arg Cys Tyr Ala His Phe Ser Gly Leu Val Cys Ala Cys Ala 450 455 460 Pro Gly Tyr Met Gly Ala Arg Cys Glu Phe Pro Val His Pro Asp Gly 465 470 475 480 Val Ser Ala Leu Pro Ala Ala Pro Pro Gly Leu Arg Pro Gly Asp Pro 485 490 495 Gln Arg Tyr Leu Leu Pro Pro Ala Leu Gly Leu Leu Val Ala Ala Gly 500 505 510 Val Ala Gly Ala Ala Leu Leu Leu Val His Val Arg Arg Arg Gly His 515 520 525 Ala Gln Asp Ala Gly Ser Arg Leu Leu Ala Gly Thr Pro Glu Pro Ser 530 535 540 Val His Ala Leu Pro Asp Ala Leu Asn Asn Leu Arg Thr Gln Glu Gly 545 550 555 560 Pro Gly Asp Val Pro Ser Ser Ser Val Asp Trp Asn Arg Pro Glu Asp 565 570 575 Val Asp Ser Arg Gly Ile Tyr Val Ile Ser Ala Pro Ser Ile Tyr Ala 580 585 590 Arg Glu Val Ala Met Pro Leu Phe Pro Pro Leu His Thr Gly Arg Ala 595 600 605 Gly Gln Arg Gln Asn Leu Leu Phe Pro Phe Pro Ser Ser Ile Leu Ser 610 615 620 Val Lys 625 <210> 112 <211> 731 <212> PRT <213> Artificial sequence <220> <223> FLAG-tagged human DLL1 full length <400> 112 Met Gly Ser Arg Cys Ala Leu Ala Leu Ala Val Leu Ser Ala Leu Leu 1 5 10 15 Cys Asp Tyr Lys Asp Asp Asp Asp Lys Gln Val Trp Ser Ser Gly Val 20 25 30 Phe Glu Leu Lys Leu Gln Glu Phe Val Asn Lys Lys Gly Leu Leu Gly 35 40 45 Asn Arg Asn Cys Cys Arg Gly Gly Ala Gly Pro Pro Pro Cys Ala Cys 50 55 60 Arg Thr Phe Phe Arg Val Cys Leu Lys His Tyr Gln Ala Ser Val Ser 65 70 75 80 Pro Glu Pro Pro Cys Thr Tyr Gly Ser Ala Val Thr Pro Val Leu Gly 85 90 95 Val Asp Ser Phe Ser Leu Pro Asp Gly Gly Gly Ala Asp Ser Ala Phe 100 105 110 Ser Asn Pro Ile Arg Phe Pro Phe Gly Phe Thr Trp Pro Gly Thr Phe 115 120 125 Ser Leu Ile Ile Glu Ala Leu His Thr Asp Ser Pro Asp Asp Leu Ala 130 135 140 Thr Glu Asn Pro Glu Arg Leu Ile Ser Arg Leu Ala Thr Gln Arg His 145 150 155 160 Leu Thr Val Gly Glu Glu Trp Ser Gln Asp Leu His Ser Ser Gly Arg 165 170 175 Thr Asp Leu Lys Tyr Ser Tyr Arg Phe Val Cys Asp Glu His Tyr Tyr 180 185 190 Gly Glu Gly Cys Ser Val Phe Cys Arg Pro Arg Asp Asp Ala Phe Gly 195 200 205 His Phe Thr Cys Gly Glu Arg Gly Glu Lys Val Cys Asn Pro Gly Trp 210 215 220 Lys Gly Pro Tyr Cys Thr Glu Pro Ile Cys Leu Pro Gly Cys Asp Glu 225 230 235 240 Gln His Gly Phe Cys Asp Lys Pro Gly Glu Cys Lys Cys Arg Val Gly 245 250 255 Trp Gln Gly Arg Tyr Cys Asp Glu Cys Ile Arg Tyr Pro Gly Cys Leu 260 265 270 His Gly Thr Cys Gln Gln Pro Trp Gln Cys Asn Cys Gln Glu Gly Trp 275 280 285 Gly Gly Leu Phe Cys Asn Gln Asp Leu Asn Tyr Cys Thr His His Lys 290 295 300 Pro Cys Lys Asn Gly Ala Thr Cys Thr Asn Thr Gly Gln Gly Ser Tyr 305 310 315 320 Thr Cys Ser Cys Arg Pro Gly Tyr Thr Gly Ala Thr Cys Glu Leu Gly 325 330 335 Ile Asp Glu Cys Asp Pro Ser Pro Cys Lys Asn Gly Gly Ser Cys Thr 340 345 350 Asp Leu Glu Asn Ser Tyr Ser Cys Thr Cys Pro Pro Gly Phe Tyr Gly 355 360 365 Lys Ile Cys Glu Leu Ser Ala Met Thr Cys Ala Asp Gly Pro Cys Phe 370 375 380 Asn Gly Gly Arg Cys Ser Asp Ser Pro Asp Gly Gly Tyr Ser Cys Arg 385 390 395 400 Cys Pro Val Gly Tyr Ser Gly Phe Asn Cys Glu Lys Lys Ile Asp Tyr 405 410 415 Cys Ser Ser Ser Pro Cys Ser Asn Gly Ala Lys Cys Val Asp Leu Gly 420 425 430 Asp Ala Tyr Leu Cys Arg Cys Gln Ala Gly Phe Ser Gly Arg His Cys 435 440 445 Asp Asp Asn Val Asp Asp Cys Ala Ser Ser Pro Cys Ala Asn Gly Gly 450 455 460 Thr Cys Arg Asp Gly Val Asn Asp Phe Ser Cys Thr Cys Pro Pro Gly 465 470 475 480 Tyr Thr Gly Arg Asn Cys Ser Ala Pro Val Ser Arg Cys Glu His Ala 485 490 495 Pro Cys His Asn Gly Ala Thr Cys His Glu Arg Gly His Arg Tyr Val 500 505 510 Cys Glu Cys Ala Arg Gly Tyr Gly Gly Pro Asn Cys Gln Phe Leu Leu 515 520 525 Pro Glu Leu Pro Pro Gly Pro Ala Val Val Asp Leu Thr Glu Lys Leu 530 535 540 Glu Gly Gln Gly Gly Pro Phe Pro Trp Val Ala Val Cys Ala Gly Val 545 550 555 560 Ile Leu Val Leu Met Leu Leu Leu Gly Cys Ala Ala Val Val Val Cys 565 570 575 Val Arg Leu Arg Leu Gln Lys His Arg Pro Pro Ala Asp Pro Cys Arg 580 585 590 Gly Glu Thr Glu Thr Met Asn Asn Leu Ala Asn Cys Gln Arg Glu Lys 595 600 605 Asp Ile Ser Val Ser Ile Ile Gly Ala Thr Gln Ile Lys Asn Thr Asn 610 615 620 Lys Lys Ala Asp Phe His Gly Asp His Ser Ala Asp Lys Asn Gly Phe 625 630 635 640 Lys Ala Arg Tyr Pro Ala Val Asp Tyr Asn Leu Val Gln Asp Leu Lys 645 650 655 Gly Asp Asp Thr Ala Val Arg Asp Ala His Ser Lys Arg Asp Thr Lys 660 665 670 Cys Gln Pro Gln Gly Ser Ser Gly Glu Glu Lys Gly Thr Pro Thr Thr 675 680 685 Leu Arg Gly Gly Glu Ala Ser Glu Arg Lys Arg Pro Asp Ser Gly Cys 690 695 700 Ser Thr Ser Lys Asp Thr Lys Tyr Gln Ser Val Tyr Val Ile Ser Glu 705 710 715 720 Glu Lys Asp Glu Cys Val Ile Ala Thr Glu Val 725 730 <210> 113 <211> 693 <212> PRT <213> Artificial sequence <220> <223> FLAG-tagged full-length human DLL4 <400> 113 Met Ala Ala Ala Ser Arg Ser Ala Ser Gly Trp Ala Leu Leu Leu Leu 1 5 10 15 Val Ala Leu Trp Gln Gln Arg Ala Ala Gly Asp Tyr Lys Asp Asp Asp 20 25 30 Asp Lys Ser Gly Val Phe Gln Leu Gln Leu Gln Glu Phe Ile Asn Glu 35 40 45 Arg Gly Val Leu Ala Ser Gly Arg Pro Cys Glu Pro Gly Cys Arg Thr 50 55 60 Phe Phe Arg Val Cys Leu Lys His Phe Gln Ala Val Val Ser Pro Gly 65 70 75 80 Pro Cys Thr Phe Gly Thr Val Ser Thr Pro Val Leu Gly Thr Asn Ser 85 90 95 Phe Ala Val Arg Asp Asp Ser Ser Gly Gly Gly Arg Asn Pro Leu Gln 100 105 110 Leu Pro Phe Asn Phe Thr Trp Pro Gly Thr Phe Ser Leu Ile Ile Glu 115 120 125 Ala Trp His Ala Pro Gly Asp Asp Leu Arg Pro Glu Ala Leu Pro Pro 130 135 140 Asp Ala Leu Ile Ser Lys Ile Ala Ile Gln Gly Ser Leu Ala Val Gly 145 150 155 160 Gln Asn Trp Leu Leu Asp Glu Gln Thr Ser Thr Leu Thr Arg Leu Arg 165 170 175 Tyr Ser Tyr Arg Val Ile Cys Ser Asp Asn Tyr Tyr Gly Asp Asn Cys 180 185 190 Ser Arg Leu Cys Lys Lys Arg Asn Asp His Phe Gly His Tyr Val Cys 195 200 205 Gln Pro Asp Gly Asn Leu Ser Cys Leu Pro Gly Trp Thr Gly Glu Tyr 210 215 220 Cys Gln Gln Pro Ile Cys Leu Ser Gly Cys His Glu Gln Asn Gly Tyr 225 230 235 240 Cys Ser Lys Pro Ala Glu Cys Leu Cys Arg Pro Gly Trp Gln Gly Arg 245 250 255 Leu Cys Asn Glu Cys Ile Pro His Asn Gly Cys Arg His Gly Thr Cys 260 265 270 Ser Thr Pro Trp Gln Cys Thr Cys Asp Glu Gly Trp Gly Gly Leu Phe 275 280 285 Cys Asp Gln Asp Leu Asn Tyr Cys Thr His His Ser Pro Cys Lys Asn 290 295 300 Gly Ala Thr Cys Ser Asn Ser Gly Gln Arg Ser Tyr Thr Cys Thr Cys 305 310 315 320 Arg Pro Gly Tyr Thr Gly Val Asp Cys Glu Leu Glu Leu Ser Glu Cys 325 330 335 Asp Ser Asn Pro Cys Arg Asn Gly Gly Ser Cys Lys Asp Gln Glu Asp 340 345 350 Gly Tyr His Cys Leu Cys Pro Pro Gly Tyr Tyr Gly Leu His Cys Glu 355 360 365 His Ser Thr Leu Ser Cys Ala Asp Ser Pro Cys Phe Asn Gly Gly Ser 370 375 380 Cys Arg Glu Arg Asn Gln Gly Ala Asn Tyr Ala Cys Glu Cys Pro Pro 385 390 395 400 Asn Phe Thr Gly Ser Asn Cys Glu Lys Lys Val Asp Arg Cys Thr Ser 405 410 415 Asn Pro Cys Ala Asn Gly Gly Gln Cys Leu Asn Arg Gly Pro Ser Arg 420 425 430 Met Cys Arg Cys Arg Pro Gly Phe Thr Gly Thr Tyr Cys Glu Leu His 435 440 445 Val Ser Asp Cys Ala Arg Asn Pro Cys Ala His Gly Gly Thr Cys His 450 455 460 Asp Leu Glu Asn Gly Leu Met Cys Thr Cys Pro Ala Gly Phe Ser Gly 465 470 475 480 Arg Arg Cys Glu Val Arg Thr Ser Ile Asp Ala Cys Ala Ser Ser Pro 485 490 495 Cys Phe Asn Arg Ala Thr Cys Tyr Thr Asp Leu Ser Thr Asp Thr Phe 500 505 510 Val Cys Asn Cys Pro Tyr Gly Phe Val Gly Ser Arg Cys Glu Phe Pro 515 520 525 Val Gly Leu Pro Pro Ser Phe Pro Trp Val Ala Val Ser Leu Gly Val 530 535 540 Gly Leu Ala Val Leu Leu Val Leu Leu Gly Met Val Ala Val Ala Val 545 550 555 560 Arg Gln Leu Arg Leu Arg Arg Pro Asp Asp Gly Ser Arg Glu Ala Met 565 570 575 Asn Asn Leu Ser Asp Phe Gln Lys Asp Asn Leu Ile Pro Ala Ala Gln 580 585 590 Leu Lys Asn Thr Asn Gln Lys Lys Glu Leu Glu Val Asp Cys Gly Leu 595 600 605 Asp Lys Ser Asn Cys Gly Lys Gln Gln Asn His Thr Leu Asp Tyr Asn 610 615 620 Leu Ala Pro Gly Pro Leu Gly Arg Gly Thr Met Pro Gly Lys Phe Pro 625 630 635 640 His Ser Asp Lys Ser Leu Gly Glu Lys Ala Pro Leu Arg Leu His Ser 645 650 655 Glu Lys Pro Glu Cys Arg Ile Ser Ala Ile Cys Ser Pro Arg Asp Ser 660 665 670 Met Tyr Gln Ser Val Cys Leu Ile Ser Glu Glu Arg Asn Glu Cys Val 675 680 685 Ile Ala Thr Glu Val 690 <210> 114 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> FLAG tag <400> 114 Asp Tyr Lys Asp Asp Asp Asp Lys 1 5 <210> 115 <211> twenty one <212> PRT <213> Artificial sequence <220> <223> Vk leader <400> 115 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp 20 <210> 116 <211> 16 <212> PRT <213> Artificial sequence <220> <223> 6His-myc tag <400> 116 His His His His His Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu 1 5 10 15 <210> 117 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Ser / Gly connectors <400> 117 Ser Gly Gly Gly Gly Ser 1 5 <210> 118 <211> twenty three <212> PRT <213> Artificial sequence <220> <223> EpCAM transmembrane domain <400> 118 Ala Gly Val Ile Ala Val Ile Val Val Val Val Ile Ala Val Val Ala 1 5 10 15 Gly Ile Val Val Leu Val Ile 20 <210> 119 <211> 26 <212> PRT <213> Artificial sequence <220> <223> EpCAM intracellular domain <400> 119 Ser Arg Lys Lys Arg Met Ala Lys Tyr Glu Lys Ala Glu Ile Lys Glu 1 5 10 15 Met Gly Glu Met His Arg Glu Leu Asn Ala 20 25 <210> 120 <211> 34 <212> PRT <213> Artificial sequence <220> <223> EGF1 <400> 120 Ala Pro Leu Val Cys Arg Ala Gly Cys Ser Pro Glu His Gly Phe Cys 1 5 10 15 Glu Gln Pro Gly Glu Cys Arg Cys Leu Glu Gly Trp Thr Gly Pro Leu 20 25 30 Cys Thr <210> 121 <211> 95 <212> PRT <213> Artificial sequence <220> <223> Hu DLL3 EGF 1+2 <400> 121 Ala Pro Leu Val Cys Arg Ala Gly Cys Ser Pro Glu His Gly Phe Cys 1 5 10 15 Glu Gln Pro Gly Glu Cys Arg Cys Leu Glu Gly Trp Thr Gly Pro Leu 20 25 30 Cys Thr Val Pro Val Ser Thr Ser Ser Cys Leu Ser Pro Arg Gly Pro 35 40 45 Ser Ser Ala Thr Thr Gly Cys Leu Val Pro Gly Pro Gly Pro Cys Asp 50 55 60 Gly Asn Pro Cys Ala Asn Gly Gly Ser Cys Ser Glu Thr Pro Arg Ser 65 70 75 80 Phe Glu Cys Thr Cys Pro Arg Gly Phe Tyr Gly Leu Arg Cys Glu 85 90 95 <210> 122 <211> 37 <212> PRT <213> Artificial Sequence <220> <223> EGF2 <400> 122 Gly Pro Gly Pro Cys Asp Gly Asn Pro Cys Ala Asn Gly Gly Ser Cys 1 5 10 15 Ser Glu Thr Pro Arg Ser Phe Glu Cys Thr Cys Pro Arg Gly Phe Tyr 20 25 30 Gly Leu Arg Cys Glu 35 <210> 123 <211> 78 <212> PRT <213> Synthetic sequence <220> <223> Hu DLL3 EGF 2+3 <400> 123 Gly Pro Gly Pro Cys Asp Gly Asn Pro Cys Ala Asn Gly Gly Ser Cys 1 5 10 15 Ser Glu Thr Pro Arg Ser Phe Glu Cys Thr Cys Pro Arg Gly Phe Tyr 20 25 30 Gly Leu Arg Cys Glu Val Ser Gly Val Thr Cys Ala Asp Gly Pro Cys 35 40 45 Phe Asn Gly Gly Leu Cys Val Gly Gly Ala Asp Pro Asp Ser Ala Tyr 50 55 60 Ile Cys His Cys Pro Pro Gly Phe Gln Gly Ser Asn Cys Glu 65 70 75 <210> 124 <211> 40 <212> PRT <213> Synthetic sequence <220> <223> EGF3 <400> 124 Ser Gly Val Thr Cys Ala Asp Gly Pro Cys Phe Asn Gly Gly Leu Cys 1 5 10 15 Val Gly Gly Ala Asp Pro Asp Ser Ala Tyr Ile Cys His Cys Pro Pro 20 25 30 Gly Phe Gln Gly Ser Asn Cys Glu 35 40 <210> 125 <211> 78 <212> PRT <213> Artificial Sequence <220> <223> Hu DLL3 EGF 3+4 <400> 125 Ser Gly Val Thr Cys Ala Asp Gly Pro Cys Phe Asn Gly Gly Leu Cys 1 5 10 15 Val Gly Gly Ala Asp Pro Asp Ser Ala Tyr Ile Cys His Cys Pro Pro 20 25 30 Gly Phe Gln Gly Ser Asn Cys Glu Lys Arg Val Asp Arg Cys Ser Leu 35 40 45 Gln Pro Cys Arg Asn Gly Gly Leu Cys Leu Asp Leu Gly His Ala Leu 50 55 60 Arg Cys Arg Cys Arg Ala Gly Phe Ala Gly Pro Arg Cys Glu 65 70 75 <210> 126 <211> 37 <212> PRT <213> Artificial Sequence <220> <223> EGF4 <400> 126 Arg Val Asp Arg Cys Ser Leu Gln Pro Cys Arg Asn Gly Gly Leu Cys 1 5 10 15 Leu Asp Leu Gly His Ala Leu Arg Cys Arg Cys Arg Ala Gly Phe Ala 20 25 30 Gly Pro Arg Cys Glu 35 <210> 127 <211> 75 <212> PRT <213> Synthetic sequence <220> <223> Hu DLL3 EGF 4+5 <400> 127 Arg Val Asp Arg Cys Ser Leu Gln Pro Cys Arg Asn Gly Gly Leu Cys 1 5 10 15 Leu Asp Leu Gly His Ala Leu Arg Cys Arg Cys Arg Ala Gly Phe Ala 20 25 30 Gly Pro Arg Cys Glu His Asp Leu Asp Asp Cys Ala Gly Arg Ala Cys 35 40 45 Ala Asn Gly Gly Thr Cys Val Glu Gly Gly Gly Ala His Arg Cys Ser 50 55 60 Cys Ala Leu Gly Phe Gly Gly Arg Asp Cys Arg 65 70 75 <210> 128 <211> 37 <212> PRT <213> Synthetic sequence <220> <223> EGF5 <400> 128 Asp Leu Asp Asp Cys Ala Gly Arg Ala Cys Ala Asn Gly Gly Thr Cys 1 5 10 15 Val Glu Gly Gly Gly Ala His Arg Cys Ser Cys Ala Leu Gly Phe Gly 20 25 30 Gly Arg Asp Cys Arg 35 <210> 129 <211> 73 <212> PRT <213> Artificial Sequence <220> <223> Hu DLL3 EGF 5+6 <400> 129 Asp Asp Cys Ala Gly Arg Ala Cys Ala Asn Gly Gly Thr Cys Val Glu 1 5 10 15 Gly Gly Gly Ala His Arg Cys Ser Cys Ala Leu Gly Phe Gly Gly Arg 20 25 30 Asp Cys Arg Glu Arg Ala Asp Pro Cys Ala Ala Arg Pro Cys Ala His 35 40 45 Gly Gly Arg Cys Tyr Ala His Phe Ser Gly Leu Val Cys Ala Cys Ala 50 55 60 Pro Gly Tyr Met Gly Ala Arg Cys Glu 65 70 <210> 130 <211> 37 <212> PRT <213> Artificial Sequence <220> <223> EGF6 <400> 130 Arg Ala Asp Pro Cys Ala Ala Arg Pro Cys Ala His Gly Gly Arg Cys 1 5 10 15 Tyr Ala His Phe Ser Gly Leu Val Cys Ala Cys Ala Pro Gly Tyr Met 20 25 30 Gly Ala Arg Cys Glu 35 <210> 131 <211> 64 <212> PRT <213> Synthetic Sequence <220> <223> Hu DLL3 EGF6 - Membrane Proximal Peptide <400> 131 Arg Ala Asp Pro Cys Ala Ala Arg Pro Cys Ala His Gly Gly Arg Cys 1 5 10 15 Tyr Ala His Phe Ser Gly Leu Val Cys Ala Cys Ala Pro Gly Tyr Met 20 25 30 Gly Ala Arg Cys Glu Phe Pro Val His Pro Asp Gly Ala Ser Ala Leu 35 40 45 Pro Ala Ala Pro Pro Gly Leu Arg Pro Gly Asp Pro Gln Arg Tyr Leu 50 55 60 <210> 132 <211> 27 <212> PRT <213> Synthetic Sequence <220> <223> Membrane Proximal Peptide <400> 132 Phe Pro Val His Pro Asp Gly Ala Ser Ala Leu Pro Ala Ala Pro Pro 1 5 10 15 Gly Leu Arg Pro Gly Asp Pro Gln Arg Tyr Leu 20 25 <210> 133 <211> 12 <212> PRT <213> Artificial sequence <220> <223> DLL3#7 LCCDR1 <400> 133 Arg Ala Ser Gln Ser Val Asn Ser Asn Phe Leu Ala 1 5 10 <210> 134 <211> 7 <212> PRT <213> Artificial sequence <220> <223> DLL3#7 LCCDR2 <400> 134 Gly Thr Ser Ser Arg Ala Thr 1 5 <210> 135 <211> 9 <212> PRT <213> Artificial sequence <220> <223> DLL3#7 LCCDR3 <400> 135 Gln Gln Tyr Gly Ser Ser Pro Trp Thr 1 5 <210> 136 <211> 10 <212> PRT <213> Artificial sequence <220> <223> DLL3#7 HCCDR1 <400> 136 Gly Phe Thr Phe Ser Ser Tyr Gly Met Phe 1 5 10 <210> 137 <211> 17 <212> PRT <213> Artificial sequence <220> <223> DLL3#7 HCCDR2 <400> 137 Val Ile Trp Leu Asp Gly Asp Asp Glu Asp Tyr Val Asp Ser Val Lys 1 5 10 15 Gly <210> 138 <211> 4 <212> PRT <213> Artificial sequence <220> <223> DLL3#7 HCCDR3 <400> 138 Val Leu Asp Tyr 1 <210> 139 <211> 17 <212> PRT <213> Artificial sequence <220> <223> DLL3#8 LCCDR1 <400> 139 Lys Ser Ser Gln Ser Val Leu Asp Thr Ser Asn Asn Lys Asn Tyr Leu 1 5 10 15 Val <210> 140 <211> 7 <212> PRT <213> Artificial sequence <220> <223> DLL3#8 LCCDR2 <400> 140 Trp Ala Ser Thr Arg Glu Ser 1 5 <210> 141 <211> 9 <212> PRT <213> Artificial sequence <220> <223> DLL3#8 LCCDR3 <400> 141 Gln His Tyr Tyr Asn Ser Pro Tyr Thr 1 5 <210> 142 <211> 10 <212> PRT <213> Artificial sequence <220> <223> DLL3#8 HCCDR1 <400> 142 Gly Tyr Thr Phe Thr Asp Tyr Tyr Met His 1 5 10 <210> 143 <211> 17 <212> PRT <213> Artificial sequence <220> <223> DLL3#8 HCCDR2 <400> 143 Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Glu Gln Lys Phe Gln 1 5 10 15 Gly <210> 144 <211> 9 <212> PRT <213> Artificial sequence <220> <223> DLL3#8 HCCDR3 <400> 144 Asp Ala Val Val Ile Pro Met Asp Tyr 1 5 <210> 145 <211> 12 <212> PRT <213> Artificial sequence <220> <223> DLL3#9 LCCDR1 <400> 145 Arg Ala Ser Gln Ser Ile Ser Arg Ser Tyr Leu Ala 1 5 10 <210> 146 <211> 7 <212> PRT <213> Artificial sequence <220> <223> DLL3#9 LCCDR2 <400> 146 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 147 <211> 9 <212> PRT <213> Artificial sequence <220> <223> DLL3#9 LCCDR3 <400> 147 Gln Gln Tyr Gly Thr Ser Pro Ile Thr 1 5 <210> 148 <211> 10 <212> PRT <213> Artificial sequence <220> <223> DLL3#9 HCCDR1 <400> 148 Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser 1 5 10 <210> 149 <211> 16 <212> PRT <213> Artificial sequence <220> <223> DLL3#9 HCCDR2 <400> 149 Tyr Arg Tyr Tyr Ser Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 150 <211> 10 <212> PRT <213> Artificial sequence <220> <223> DLL3#9 HCCDR3 <400> 150 Ile Gly Val Ala Gly Phe Tyr Phe Asp Tyr 1 5 10 <210> 151 <211> 12 <212> PRT <213> Artificial sequence <220> <223> DLL3#10 LCCDR1 <400> 151 Arg Ala Ser Gln Ser Leu Asn Ser Ile Phe Leu Ala 1 5 10 <210> 152 <211> 7 <212> PRT <213> Artificial sequence <220> <223> DLL3#10 LCCDR2 <400> 152 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 153 <211> 9 <212> PRT <213> Artificial sequence <220> <223> DLL3#10 LCCDR3 <400> 153 Gln Gln Tyr Gly Gly Ser Met Asn Thr 1 5 <210> 154 <211> 10 <212> PRT <213> Artificial sequence <220> <223> DLL3#10 HCCDR1 <400> 154 Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His 1 5 10 <210> 155 <211> 17 <212> PRT <213> Artificial sequence <220> <223> DLL3#10 HCCDR2 <400> 155 Trp Ile Asn Pro Asn Ser Gly Gly Thr Ile Phe Ala Gln Arg Phe Gln 1 5 10 15 Gly <210> 156 <211> 12 <212> PRT <213> Artificial sequence <220> <223> DLL3#10 HCCDR3 <400> 156 Asp Phe Gly Asp Thr Val Gly Asn Ala Phe Asp Ile 1 5 10 <210> 157 <211> 10 <212> PRT <213> Artificial sequence <220> <223> DLL3#11 LCCDR1 <400> 157 Ser Ala Ser Ser Ser Val Thr Tyr Ile His 1 5 10 <210> 158 <211> 7 <212> PRT <213> Artificial sequence <220> <223> DLL3#11 LCCDR2 <400> 158 Arg Thr Ser Tyr Leu Ala Ser 1 5 <210> 159 <211> 9 <212> PRT <213> Artificial sequence <220> <223> DLL3#11 LCCDR3 <400> 159 Gln Gln Arg Ser Ser Tyr Pro Arg Thr 1 5 <210> 160 <211> 10 <212> PRT <213> Artificial sequence <220> <223> DLL3#11 HCCDR1 <400> 160 Gly Tyr Ala Phe Ser Asp Tyr Trp Ile Thr 1 5 10 <210> 161 <211> 17 <212> PRT <213> Artificial sequence <220> <223> DLL3#11 HCCDR2 <400> 161 Asp Ile Tyr Pro Gly Ser Gly Ser Thr Lys Ser Ser Glu Lys Phe Lys 1 5 10 15 Asn <210> 162 <211> 11 <212> PRT <213> Artificial sequence <220> <223> DLL3#11 HCCDR3 <400> 162 Leu Tyr Tyr Tyr Gly Ser His Tyr Leu Asp Thr 1 5 10 <210> 163 <211> 10 <212> PRT <213> Artificial sequence <220> <223> DLL3#12 LCCDR1 <400> 163 Ser Ala Ser Ser Ser Val Thr Tyr Ile His 1 5 10 <210> 164 <211> 7 <212> PRT <213> Artificial sequence <220> <223> DLL3#12 LCCDR2 <400> 164 Arg Thr Ser Tyr Leu Ala Ser 1 5 <210> 165 <211> 9 <212> PRT <213> Artificial sequence <220> <223> DLL3#12 LCCDR3 <400> 165 Gln Gln Arg Ser Ser Tyr Pro Arg Thr 1 5 <210> 166 <211> 10 <212> PRT <213> Artificial sequence <220> <223> DLL3#12 HCCDR1 <400> 166 Gly Tyr Ala Phe Ser Asp Tyr Trp Ile Thr 1 5 10 <210> 167 <211> 17 <212> PRT <213> Artificial sequence <220> <223> DLL3#12 HCCDR2 <400> 167 Asp Ile Tyr Pro Gly Ser Gly Ser Thr Lys Ser Ser Glu Lys Phe Lys 1 5 10 15 Asn <210> 168 <211> 11 <212> PRT <213> Artificial sequence <220> <223> DLL3#12 HCCDR3 <400> 168 Leu Tyr Tyr Tyr Gly Ser Tyr Tyr Leu Asp Thr 1 5 10 <210> 169 <211> 16 <212> PRT <213> Artificial sequence <220> <223> DLL3#13 LCCDR1 <400> 169 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 170 <211> 7 <212> PRT <213> Artificial sequence <220> <223> DLL3#13 LCCDR2 <400> 170 Lys Val Ser Asn Arg Phe Ser 1 5 <210> 171 <211> 9 <212> PRT <213> Artificial sequence <220> <223> DLL3#13 LCCDR3 <400> 171 Phe Gln Gly Ser His Val Pro Tyr Thr 1 5 <210> 172 <211> 10 <212> PRT <213> Artificial sequence <220> <223> DLL3#13 HCCDR1 <400> 172 Gly Tyr Thr Phe Thr Asn Tyr Gly Val Thr 1 5 10 <210> 173 <211> 17 <212> PRT <213> Artificial sequence <220> <223> DLL3#13 HCCDR2 <400> 173 Trp Ile Asn Thr Tyr Ser Gly Ala Pro Thr Tyr Ala Asp Asp Phe Asn 1 5 10 15 Gly <210> 174 <211> 11 <212> PRT <213> Artificial sequence <220> <223> DLL3#13 HCCDR3 <400> 174 Leu Asp Asp Tyr Asp Leu Tyr Tyr Phe Asp Tyr 1 5 10 <210> 175 <211> 15 <212> PRT <213> Artificial sequence <220> <223> DLL3#14 LCCDR1 <400> 175 Lys Ala Ser Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr Met Asn 1 5 10 15 <210> 176 <211> 7 <212> PRT <213> Artificial sequence <220> <223> DLL3#14 LCCDR2 <400> 176 Ala Ala Ser Thr Leu Glu Ser 1 5 <210> 177 <211> 9 <212> PRT <213> Artificial sequence <220> <223> DLL3#14 LCCDR3 <400> 177 Gln Gln Ser Asp Glu Asp Pro Trp Thr 1 5 <210> 178 <211> 10 <212> PRT <213> Artificial sequence <220> <223> DLL3#14 HCCDR1 <400> 178 Gly Tyr Thr Phe Thr Asp Tyr Tyr Ile His 1 5 10 <210> 179 <211> 17 <212> PRT <213> Artificial sequence <220> <223> DLL3#14 HCCDR2 <400> 179 Tyr Ile Tyr Pro Gly Asn Ser Tyr Thr Ala Tyr Asn Gln Lys Phe Lys 1 5 10 15 Asp <210> 180 <211> 8 <212> PRT <213> Artificial sequence <220> <223> DLL3#14 HCCDR3 <400> 180 Ser Gly Gly Ser Ala Met Asp Tyr 1 5 <210> 181 <211> 15 <212> PRT <213> Artificial sequence <220> <223> DLL3#15 LCCDR1 <400> 181 Lys Ala Ser Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr Leu Asn 1 5 10 15 <210> 182 <211> 7 <212> PRT <213> Artificial sequence <220> <223> DLL3#15 LCCDR2 <400> 182 Ala Ala Ser Asn Leu Glu Ser 1 5 <210> 183 <211> 9 <212> PRT <213> Artificial sequence <220> <223> DLL3#15 LCCDR3 <400> 183 Gln Gln Ser Ser Glu Asp Pro Arg Thr 1 5 <210> 184 <211> 10 <212> PRT <213> Artificial sequence <220> <223> DLL3#15 HCCDR1 <400> 184 Gly Tyr Thr Phe Thr Asn Tyr Gly Met Asn 1 5 10 <210> 185 <211> 17 <212> PRT <213> Artificial sequence <220> <223> DLL3#15 HCCDR2 <400> 185 Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys 1 5 10 15 Gly <210> 186 <211> 12 <212> PRT <213> Artificial sequence <220> <223> DLL3#15 HCCDR3 <400> 186 Phe His Phe Ser Ser Asn Gly Asp Ala Met Asp Asn 1 5 10 <210> 187 <211> 11 <212> PRT <213> Artificial sequence <220> <223> DLL3#16 LCCDR1 <400> 187 Arg Ala Ser Gln Ser Val Ser Asp Trp Leu Ala 1 5 10 <210> 188 <211> 7 <212> PRT <213> Artificial sequence <220> <223> DLL3#16 LCCDR2 <400> 188 Arg Ala Ser Ser Leu Glu Ser 1 5 <210> 189 <211> 9 <212> PRT <213> Artificial sequence <220> <223> DLL3#16 LCCDR3 <400> 189 Gln Leu Tyr Asn Ser Tyr Ser Pro Thr 1 5 <210> 190 <211> 10 <212> PRT <213> Artificial sequence <220> <223> DLL3#16 HCCDR1 <400> 190 Gly Phe Thr Phe Ser Ser Tyr Trp Met Thr 1 5 10 <210> 191 <211> 17 <212> PRT <213> Artificial sequence <220> <223> DLL3#16 HCCDR2 <400> 191 Asn Ile Lys Glu Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys 1 5 10 15 Gly <210> 192 <211> 7 <212> PRT <213> Artificial sequence <220> <223> DLL3#16 HCCDR3 <400> 192 Asp Trp Gly Tyr Phe Asp Tyr 1 5 <210> 193 <211> 11 <212> PRT <213> Artificial sequence <220> <223> DLL3#17 LCCDR1 <400> 193 Arg Ala Ser Glu Asn Ile Tyr Tyr Ser Leu Ala 1 5 10 <210> 194 <211> 7 <212> PRT <213> Artificial sequence <220> <223> DLL3#17 LCCDR2 <400> 194 Asn Thr Asn Ser Leu Glu Asp 1 5 <210> 195 <211> 9 <212> PRT <213> Artificial sequence <220> <223> DLL3#17 LCCDR3 <400> 195 Lys Gln Ala Tyr Asp Phe Pro Leu Thr 1 5 <210> 196 <211> 10 <212> PRT <213> Artificial sequence <220> <223> DLL3#17 HCCDR1 <400> 196 Gly Tyr Thr Phe Ile Ser Tyr Tyr Ile His 1 5 10 <210> 197 <211> 17 <212> PRT <213> Artificial sequence <220> <223> DLL3#17 HCCDR2 <400> 197 Trp Ile Tyr Pro Gly Asp Gly Ser Thr Asn Asn Asn Glu Lys Phe Lys 1 5 10 15 Gly <210> 198 <211> 8 <212> PRT <213> Artificial sequence <220> <223> DLL3#17 HCCDR3 <400> 198 Gly Glu Gly Asn Ala Met Asp Asp 1 5 <210> 199 <211> 11 <212> PRT <213> Artificial sequence <220> <223> DLL3#18 LCCDR1 <400> 199 Arg Ala Ser Glu Asn Ile Tyr Tyr Ser Leu Ala 1 5 10 <210> 200 <211> 7 <212> PRT <213> Artificial sequence <220> <223> DLL3#18 LCCDR2 <400> 200 Asn Ala Asn Ser Leu Glu Asp 1 5 <210> 201 <211> 9 <212> PRT <213> Artificial sequence <220> <223> DLL3#18 LCCDR3 <400> 201 Lys Gln Ala Tyr Asp Val Pro Leu Thr 1 5 <210> 202 <211> 10 <212> PRT <213> Artificial sequence <220> <223> DLL3#18 HCCDR1 <400> 202 Gly Tyr Thr Phe Thr Ala Tyr Phe Ile His 1 5 10 <210> 203 <211> 17 <212> PRT <213> Artificial sequence <220> <223> DLL3#18 HCCDR2 <400> 203 Tyr Ile Asp Pro Phe Asn Asp Asp Thr Asn Tyr Asn Val Lys Phe Lys 1 5 10 15 Gly <210> 204 <211> 8 <212> PRT <213> Artificial sequence <220> <223> DLL3#18 HCCDR3 <400> 204 Gly Thr Ser Ala Thr Leu Asp Tyr 1 5 <210> 205 <211> 108 <212> PRT <213> Artificial sequence <220> <223> DLL3#7 VL <400> 205 Glu Ile Val Leu Thr Gln Ser Pro Asp Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Ser Asn 20 25 30 Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Thr Pro Arg Leu Leu 35 40 45 Ile Phe Gly Thr Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Arg 100 105 <210> 206 <211> 113 <212> PRT <213> artificial sequence <220> <223> DLL3#7 VH <400> 206 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Trp Leu Asp Gly Asp Asp Glu Asp Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Val Asp Asp Thr Ala Ile Tyr Tyr Cys 85 90 95 Ala Arg Val Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110 Looking <210> 207 <211> 113 <212> PRT <213> artificial sequence <220> <223> DLL3#8 VL <400> 207 Asp Ile Val Met Ala Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Asp Thr 20 25 30 Ser Asn Asn Lys Asn Tyr Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln His 85 90 95 Tyr Tyr Asn Ser Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile 100 105 110 Lys <210> 208 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> DLL3#8 VH <400> 208 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Glu Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Asn Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Asp Ala Val Val Ile Pro Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 209 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> DLL3#9 VL <400> 209 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Arg Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Thr Ser Pro 85 90 95 Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 210 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> DLL3#9 VH <400> 210 Gln Val His Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Thr Pro Gly Lys Gly Leu Asp Trp Ile 35 40 45 Gly Tyr Arg Tyr Tyr Ser Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Leu Asp Met Ser Asn Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Ile Tyr Tyr Cys Ala 85 90 95 Ser Ile Gly Val Ala Gly Phe Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 211 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> DLL3#10 VL <400> 211 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Leu Asn Ser Ile 20 25 30 Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Trp Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Tyr Gly Gly Ser Met 85 90 95 Asn Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 212 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> DLL3#10 VH <400> 212 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Met His Trp Val Arg Leu Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Ile Phe Ala Gln Arg Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Val Tyr 65 70 75 80 Met Asp Leu Asn Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Phe Gly Asp Thr Val Gly Asn Ala Phe Asp Ile Trp Gly 100 105 110 Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 213 <211> 106 <212> PRT <213> Artificial Sequence <220> <223> DLL3#11 VL <400> 213 Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Thr Tyr Ile 20 25 30 His Trp Phe Gln Gln Asn Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr 35 40 45 Arg Thr Ser Tyr Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro Arg Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 214 <211> 120 <212> PRT <213> artificial sequence <220> <223> DLL3#11 VH <400> 214 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Gln Pro Gly Ser 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Asp Tyr 20 25 30 Trp Ile Thr Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asp Ile Tyr Pro Gly Ser Gly Ser Thr Lys Ser Ser Glu Lys Phe 50 55 60 Lys Asn Lys Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Lys Ala Tyr 65 70 75 80 Ile Gln Phe Ser Ser Leu Thr Pro Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Val Ser Leu Tyr Tyr Tyr Gly Ser His Tyr Leu Asp Thr Trp Gly Gln 100 105 110 Gly Thr Thr Leu Thr Val Ser Ser 115 120 <210> 215 <211> 106 <212> PRT <213> artificial sequence <220> <223> DLL3#12 VL <400> 215 Gln Val Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Thr Tyr Ile 20 25 30 His Trp Phe Gln Gln Asn Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr 35 40 45 Arg Thr Ser Tyr Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro Arg Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 216 <211> 120 <212> PRT <213> Synthetic Sequence <220> <223> DLL3#12 VH <400> 216 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Phe Val Gln Pro Gly Ser 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Asp Tyr 20 25 30 Trp Ile Thr Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asp Ile Tyr Pro Gly Ser Gly Ser Thr Lys Ser Ser Glu Lys Phe 50 55 60 Lys Asn Arg Ala Thr Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr 65 70 75 80 Ile Gln Phe Ser Ser Leu Thr Pro Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Val Ser Leu Tyr Tyr Tyr Gly Ser Tyr Tyr Leu Asp Thr Trp Gly Gln 100 105 110 Gly Thr Thr Leu Thr Val Ser Ser 115 120 <210> 217 <211> 112 <212> PRT <213> artificial sequence <220> <223> DLL3#13 VL <400> 217 Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ala Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 218 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> DLL3#13 VH <400> 218 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Val Thr Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 35 40 45 Gly Trp Ile Asn Thr Tyr Ser Gly Ala Pro Thr Tyr Ala Asp Asp Phe 50 55 60 Asn Gly Arg Phe Ala Leu Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Ala Arg Leu Asp Asp Tyr Asp Leu Tyr Tyr Phe Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Ala Leu Thr Val Ser Ser 115 120 <210> 219 <211> 111 <212> PRT <213> artificial sequence <220> <223> DLL3#14 VL <400> 219 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Val Ser Leu Gly 1 5 10 15 Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp 20 25 30 Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Glu Ser Gly Ile Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 65 70 75 80 Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asp 85 90 95 Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 220 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> DLL3#14 VH <400> 220 Gln Ile Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Val 1 5 10 15 Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Ile 20 25 30 His Trp Met Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Tyr 35 40 45 Ile Tyr Pro Gly Asn Ser Tyr Thr Ala Tyr Asn Gln Lys Phe Lys Asp 50 55 60 Lys Ala Thr Leu Thr Ala Asp Asn Pro Ser Ser Thr Ala Tyr Met Gln 65 70 75 80 Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg 85 90 95 Ser Gly Gly Ser Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr 100 105 110 Val Ser Ser 115 <210> 221 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> DLL3#15 VL <400> 221 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp 20 25 30 Gly Asp Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 65 70 75 80 Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Ser 85 90 95 Glu Asp Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 222 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> DLL3#15 VH <400> 222 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Met Ala Thr Tyr Phe Cys 85 90 95 Thr Lys Phe His Phe Ser Ser Asn Gly Asp Ala Met Asp Asn Trp Gly 100 105 110 Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 223 <211> 107 <212> PRT <213> artificial sequence <220> <223> DLL3#16 VL <400> 223 Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Ser Asp Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Phe Leu Ile 35 40 45 Tyr Arg Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Ala Asp Phe Ala Thr Tyr Tyr Cys Gln Leu Tyr Asn Ser Tyr Ser Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 224 <211> 116 <212> PRT <213> artificial sequence <220> <223> DLL3#16 VH <400> 224 Glu Val His Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asn Ile Lys Glu Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Ala Arg Asp Trp Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> 225 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> DLL3#17 VL <400> 225 Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ala Ala Ser Val Gly 1 5 10 15 Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Tyr Ser 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Ile 35 40 45 Tyr Asn Thr Asn Ser Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Gln Tyr Ser Met Lys Ile Asn Ser Met Gln Pro 65 70 75 80 Glu Asp Thr Ala Thr Tyr Phe Cys Lys Gln Ala Tyr Asp Phe Pro Leu 85 90 95 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100 105 <210> 226 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> DLL3#17 VH <400> 226 Gln Ile Gln Leu Gln Gln Ser Gly Pro Glu Val Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Ser Tyr 20 25 30 Tyr Ile His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Tyr Pro Gly Asp Gly Ser Thr Asn Asn Asn Glu Lys Phe 50 55 60 Lys Gly Lys Thr Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Leu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Arg Gly Glu Gly Asn Ala Met Asp Asp Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 227 <211> 107 <212> PRT <213> artificial sequence <220> <223> DLL3#18 VL <400> 227 Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ala Ala Ser Val Gly 1 5 10 15 Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Tyr Ser 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Ile 35 40 45 Tyr Asn Ala Asn Ser Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Gln Tyr Ser Met Lys Ile Asn Asn Met Gln Pro 65 70 75 80 Glu Asp Thr Ala Thr Tyr Phe Cys Lys Gln Ala Tyr Asp Val Pro Leu 85 90 95 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100 105 <210> 228 <211> 117 <212> PRT <213> Artificial sequence <220> <223> DLL3#18 VH <400> 228 Gln Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Glu Ala Ser Gly Tyr Thr Phe Thr Ala Tyr 20 25 30 Phe Ile His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Asp Pro Phe Asn Asp Asp Thr Asn Tyr Asn Val Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Ser Asp Thr Ser Ser Ser Ile Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ser Phe Tyr Tyr Cys 85 90 95 Ala Arg Gly Thr Ser Ala Thr Leu Asp Tyr Trp Gly His Gly Thr Thr 100 105 110 Leu Thr Val Ser Ser 115 <210> 229 <211> 469 <212> PRT <213> Artificial Sequence <220> <223> DLL3#7 scFab <400> 229 Glu Ile Val Leu Thr Gln Ser Pro Asp Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Ser Asn 20 25 30 Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Thr Pro Arg Leu Leu 35 40 45 Ile Phe Gly Thr Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Arg Arg Thr Val Ala 100 105 110 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 145 150 155 160 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser 210 215 220 Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly 225 230 235 240 Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Val Gln 245 250 255 Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg 260 265 270 Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met Phe 275 280 285 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile 290 295 300 Trp Leu Asp Gly Asp Asp Glu Asp Tyr Val Asp Ser Val Lys Gly Arg 305 310 315 320 Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met 325 330 335 Asn Ser Leu Arg Val Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Val 340 345 350 Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser 355 360 365 Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr 370 375 380 Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro 385 390 395 400 Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val 405 410 415 His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser 420 425 430 Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile 435 440 445 Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val 450 455 460 Glu Pro Lys Ser Cys 465 <210> 230 <211> 479 <212> PRT <213> artificial sequence <220> <223> DLL3#8 scFab <400> 230 Asp Ile Val Met Ala Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Asp Thr 20 25 30 Ser Asn Asn Lys Asn Tyr Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln His 85 90 95 Tyr Tyr Asn Ser Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile 100 105 110 Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp 115 120 125 Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn 130 135 140 Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu 145 150 155 160 Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp 165 170 175 Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr 180 185 190 Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser 195 200 205 Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly 210 215 220 Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu 225 230 235 240 Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly 245 250 255 Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro 260 265 270 Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr 275 280 285 Asp Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu 290 295 300 Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Glu Gln 305 310 315 320 Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr 325 330 335 Ala Tyr Met Glu Leu Asn Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Thr Arg Asp Ala Val Val Ile Pro Met Asp Tyr Trp Gly Gln 355 360 365 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 370 375 380 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 385 390 395 400 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 405 410 415 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 420 425 430 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 435 440 445 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 450 455 460 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 465 470 475 <210> 231 <211> 474 <212> PRT <213> artificial sequence <220> <223> DLL3#9 scFab <400> 231 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Arg Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Thr Ser Pro 85 90 95 Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala 100 105 110 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 145 150 155 160 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser 210 215 220 Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly 225 230 235 240 Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Val His 245 250 255 Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser 260 265 270 Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser 275 280 285 Trp Ile Arg Gln Thr Pro Gly Lys Gly Leu Asp Trp Ile Gly Tyr Arg 290 295 300 Tyr Tyr Ser Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val 305 310 315 320 Thr Ile Ser Leu Asp Met Ser Asn Asn Gln Phe Ser Leu Lys Leu Ser 325 330 335 Ser Val Thr Ala Ala Asp Thr Ala Ile Tyr Tyr Cys Ala Ser Ile Gly 340 345 350 Val Ala Gly Phe Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr 355 360 365 Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 370 375 380 Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 385 390 395 400 Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 405 410 415 Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 420 425 430 Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 435 440 445 Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys 450 455 460 Val Asp Lys Arg Val Glu Pro Lys Ser Cys 465 470 <210> 232 <211> 477 <212> PRT <213> artificial sequence <220> <223> DLL3#10 scFab <400> 232 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Leu Asn Ser Ile 20 25 30 Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Trp Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Tyr Gly Gly Ser Met 85 90 95 Asn Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala 100 105 110 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 145 150 155 160 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser 210 215 220 Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly 225 230 235 240 Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Val Gln 245 250 255 Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys 260 265 270 Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His 275 280 285 Trp Val Arg Leu Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile 290 295 300 Asn Pro Asn Ser Gly Gly Thr Ile Phe Ala Gln Arg Phe Gln Gly Arg 305 310 315 320 Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Val Tyr Met Asp Leu 325 330 335 Asn Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp 340 345 350 Phe Gly Asp Thr Val Gly Asn Ala Phe Asp Ile Trp Gly Gln Gly Thr 355 360 365 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 370 375 380 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 385 390 395 400 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 405 410 415 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 420 425 430 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 435 440 445 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 450 455 460 Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 465 470 475 <210> 233 <211> 474 <212> PRT <213> Artificial Sequence <220> <223> DLL3#11 scFab <400> 233 Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Thr Tyr Ile 20 25 30 His Trp Phe Gln Gln Asn Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr 35 40 45 Arg Thr Ser Tyr Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro Arg Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro 100 105 110 Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr 115 120 125 Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys 130 135 140 Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu 145 150 155 160 Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser 165 170 175 Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala 180 185 190 Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe 195 200 205 Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser Ser Gly 210 215 220 Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly Ser Gly 225 230 235 240 Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Val Gln Leu Gln 245 250 255 Gln Pro Gly Ala Glu Leu Val Gln Pro Gly Ser Ser Val Lys Met Ser 260 265 270 Cys Lys Ala Ser Gly Tyr Ala Phe Ser Asp Tyr Trp Ile Thr Trp Val 275 280 285 Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Asp Ile Tyr Pro 290 295 300 Gly Ser Gly Ser Thr Lys Ser Ser Glu Lys Phe Lys Asn Lys Ala Thr 305 310 315 320 Leu Thr Ala Asp Thr Ser Ser Ser Lys Ala Tyr Ile Gln Phe Ser Ser 325 330 335 Leu Thr Pro Glu Asp Ser Ala Val Tyr Tyr Cys Val Ser Leu Tyr Tyr 340 345 350 Tyr Gly Ser His Tyr Leu Asp Thr Trp Gly Gln Gly Thr Thr Leu Thr 355 360 365 Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 370 375 380 Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 385 390 395 400 Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 405 410 415 Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 420 425 430 Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 435 440 445 Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys 450 455 460 Val Asp Lys Arg Val Glu Pro Lys Ser Cys 465 470 <210> 234 <211> 474 <212> PRT <213> artificial sequence <220> <223> DLL3#12 scFab <400> 234 Gln Val Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Thr Tyr Ile 20 25 30 His Trp Phe Gln Gln Asn Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr 35 40 45 Arg Thr Ser Tyr Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro Arg Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro 100 105 110 Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr 115 120 125 Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys 130 135 140 Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu 145 150 155 160 Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser 165 170 175 Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala 180 185 190 Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe 195 200 205 Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser Ser Gly 210 215 220 Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly Ser Gly 225 230 235 240 Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Val Gln Leu Gln 245 250 255 Gln Pro Gly Ala Glu Phe Val Gln Pro Gly Ser Ser Val Lys Met Ser 260 265 270 Cys Lys Ala Ser Gly Tyr Ala Phe Ser Asp Tyr Trp Ile Thr Trp Val 275 280 285 Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Asp Ile Tyr Pro 290 295 300 Gly Ser Gly Ser Thr Lys Ser Ser Glu Lys Phe Lys Asn Arg Ala Thr 305 310 315 320 Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr Ile Gln Phe Ser Ser 325 330 335 Leu Thr Pro Glu Asp Ser Ala Val Tyr Tyr Cys Val Ser Leu Tyr Tyr 340 345 350 Tyr Gly Ser Tyr Tyr Leu Asp Thr Trp Gly Gln Gly Thr Thr Leu Thr 355 360 365 Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 370 375 380 Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 385 390 395 400 Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 405 410 415 Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 420 425 430 Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 435 440 445 Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys 450 455 460 Val Asp Lys Arg Val Glu Pro Lys Ser Cys 465 470 <210> 235 <211> 480 <212> PRT <213> artificial sequence <220> <223> DLL3#13 scFab <400> 235 Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ala Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser 210 215 220 Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly 225 230 235 240 Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly 245 250 255 Ser Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly 260 265 270 Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn 275 280 285 Tyr Gly Val Thr Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp 290 295 300 Met Gly Trp Ile Asn Thr Tyr Ser Gly Ala Pro Thr Tyr Ala Asp Asp 305 310 315 320 Phe Asn Gly Arg Phe Ala Leu Ser Leu Glu Thr Ser Ala Ser Thr Ala 325 330 335 Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe 340 345 350 Cys Ala Arg Leu Asp Asp Tyr Asp Leu Tyr Tyr Phe Asp Tyr Trp Gly 355 360 365 Gln Gly Thr Ala Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 370 375 380 Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 385 390 395 400 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 405 410 415 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 420 425 430 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 435 440 445 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 450 455 460 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 465 470 475 480 <210> 236 <211> 474 <212> PRT <213> artificial sequence <220> <223> DLL3#14 scFab <400> 236 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Val Ser Leu Gly 1 5 10 15 Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp 20 25 30 Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Glu Ser Gly Ile Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 65 70 75 80 Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asp 85 90 95 Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 100 105 110 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 115 120 125 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 130 135 140 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 145 150 155 160 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 165 170 175 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 180 185 190 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 195 200 205 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu 210 215 220 Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys 225 230 235 240 Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser 245 250 255 Gln Ile Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Val 260 265 270 Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Ile 275 280 285 His Trp Met Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Tyr 290 295 300 Ile Tyr Pro Gly Asn Ser Tyr Thr Ala Tyr Asn Gln Lys Phe Lys Asp 305 310 315 320 Lys Ala Thr Leu Thr Ala Asp Asn Pro Ser Ser Thr Ala Tyr Met Gln 325 330 335 Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg 340 345 350 Ser Gly Gly Ser Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr 355 360 365 Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 370 375 380 Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 385 390 395 400 Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 405 410 415 Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 420 425 430 Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 435 440 445 Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys 450 455 460 Val Asp Lys Arg Val Glu Pro Lys Ser Cys 465 470 <210> 237 <211> 480 <212> PRT <213> artificial sequence <220> <223> DLL3#15 scFab <400> 237 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp 20 25 30 Gly Asp Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 65 70 75 80 Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Ser 85 90 95 Glu Asp Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 100 105 110 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 115 120 125 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 130 135 140 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 145 150 155 160 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 165 170 175 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 180 185 190 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 195 200 205 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu 210 215 220 Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys 225 230 235 240 Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser 245 250 255 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 260 265 270 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 275 280 285 Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 290 295 300 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 305 310 315 320 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 325 330 335 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Met Ala Thr Tyr Phe Cys 340 345 350 Thr Lys Phe His Phe Ser Ser Asn Gly Asp Ala Met Asp Asn Trp Gly 355 360 365 Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 370 375 380 Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 385 390 395 400 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 405 410 415 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 420 425 430 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 435 440 445 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 450 455 460 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 465 470 475 480 <210> 238 <211> 471 <212> PRT <213> Artificial Sequence <220> <223> DLL3#16 scFab <400> 238 Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Ser Asp Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Phe Leu Ile 35 40 45 Tyr Arg Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Ala Asp Phe Ala Thr Tyr Tyr Cys Gln Leu Tyr Asn Ser Tyr Ser Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser Ser 210 215 220 Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly Ser 225 230 235 240 Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Glu Val His Leu 245 250 255 Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu 260 265 270 Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Thr Trp 275 280 285 Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys 290 295 300 Glu Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe 305 310 315 320 Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn 325 330 335 Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Asp Trp 340 345 350 Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 355 360 365 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 370 375 380 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 385 390 395 400 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 405 410 415 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 420 425 430 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 435 440 445 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 450 455 460 Arg Val Glu Pro Lys Ser Cys 465 470 <210> 239 <211> 472 <212> PRT <213> artificial sequence <220> <223> DLL3#17 scFab <400> 239 Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ala Ala Ser Val Gly 1 5 10 15 Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Tyr Ser 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Ile 35 40 45 Tyr Asn Thr Asn Ser Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Gln Tyr Ser Met Lys Ile Asn Ser Met Gln Pro 65 70 75 80 Glu Asp Thr Ala Thr Tyr Phe Cys Lys Gln Ala Tyr Asp Phe Pro Leu 85 90 95 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser Ser 210 215 220 Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly Ser 225 230 235 240 Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Ile Gln Leu 245 250 255 Gln Gln Ser Gly Pro Glu Val Val Lys Pro Gly Ala Ser Val Lys Ile 260 265 270 Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Ser Tyr Tyr Ile His Trp 275 280 285 Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Trp Ile Tyr 290 295 300 Pro Gly Asp Gly Ser Thr Asn Asn Asn Glu Lys Phe Lys Gly Lys Thr 305 310 315 320 Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Leu Leu Ser 325 330 335 Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Gly Glu 340 345 350 Gly Asn Ala Met Asp Asp Trp Gly Gln Gly Thr Ser Val Thr Val Ser 355 360 365 Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser 370 375 380 Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp 385 390 395 400 Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr 405 410 415 Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr 420 425 430 Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln 435 440 445 Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp 450 455 460 Lys Arg Val Glu Pro Lys Ser Cys 465 470 <210> 240 <211> 472 <212> PRT <213> artificial sequence <220> <223> DLL3#18 scFab <400> 240 Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ala Ala Ser Val Gly 1 5 10 15 Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Tyr Ser 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Ile 35 40 45 Tyr Asn Ala Asn Ser Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Gln Tyr Ser Met Lys Ile Asn Asn Met Gln Pro 65 70 75 80 Glu Asp Thr Ala Thr Tyr Phe Cys Lys Gln Ala Tyr Asp Val Pro Leu 85 90 95 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser Ser 210 215 220 Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly Ser 225 230 235 240 Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Val Gln Leu 245 250 255 Gln Gln Ser Gly Pro Asp Leu Val Lys Pro Gly Ala Ser Val Lys Met 260 265 270 Ser Cys Glu Ala Ser Gly Tyr Thr Phe Thr Ala Tyr Phe Ile His Trp 275 280 285 Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Asp 290 295 300 Pro Phe Asn Asp Asp Thr Asn Tyr Asn Val Lys Phe Lys Gly Lys Ala 305 310 315 320 Thr Leu Thr Ser Asp Thr Ser Ser Ser Ile Ala Tyr Met Glu Leu Ser 325 330 335 Ser Leu Thr Ser Glu Asp Ser Ser Phe Tyr Tyr Cys Ala Arg Gly Thr 340 345 350 Ser Ala Thr Leu Asp Tyr Trp Gly His Gly Thr Thr Leu Thr Val Ser 355 360 365 Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser 370 375 380 Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp 385 390 395 400 Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr 405 410 415 Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr 420 425 430 Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln 435 440 445 Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp 450 455 460 Lys Arg Val Glu Pro Lys Ser Cys 465 470 <210> 241 <211> 695 <212> PRT <213> Artificial Sequence <220> <223> DLL3 #7 Chain <400> 241 Glu Ile Val Leu Thr Gln Ser Pro Asp Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Ser Asn 20 25 30 Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Thr Pro Arg Leu Leu 35 40 45 Ile Phe Gly Thr Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Arg Arg Thr Val Ala 100 105 110 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 145 150 155 160 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser 210 215 220 Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly 225 230 235 240 Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Val Gln 245 250 255 Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg 260 265 270 Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met Phe 275 280 285 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile 290 295 300 Trp Leu Asp Gly Asp Asp Glu Asp Tyr Val Asp Ser Val Lys Gly Arg 305 310 315 320 Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met 325 330 335 Asn Ser Leu Arg Val Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Val 340 345 350 Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser 355 360 365 Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr 370 375 380 Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro 385 390 395 400 Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val 405 410 415 His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser 420 425 430 Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile 435 440 445 Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val 450 455 460 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 465 470 475 480 Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 485 490 495 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 500 505 510 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 515 520 525 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 530 535 540 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 545 550 555 560 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 565 570 575 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 580 585 590 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr 595 600 605 Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser 610 615 620 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 625 630 635 640 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 645 650 655 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 660 665 670 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 675 680 685 Ser Leu Ser Leu Ser Pro Gly 690 695 <210> 242 <211> 705 <212> PRT <213> Artificial sequence <220> <223> DLL3#8 chain <400> 242 Asp Ile Val Met Ala Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Asp Thr 20 25 30 Ser Asn Asn Lys Asn Tyr Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln His 85 90 95 Tyr Tyr Asn Ser Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile 100 105 110 Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp 115 120 125 Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn 130 135 140 Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu 145 150 155 160 Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp 165 170 175 Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr 180 185 190 Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser 195 200 205 Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly 210 215 220 Ser Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu 225 230 235 240 Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly 245 250 255 Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro 260 265 270 Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr 275 280 285 Asp Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu 290 295 300 Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Glu Gln 305 310 315 320 Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr 325 330 335 Ala Tyr Met Glu Leu Asn Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr 340 345 350 Tyr Cys Thr Arg Asp Ala Val Val Ile Pro Met Asp Tyr Trp Gly Gln 355 360 365 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 370 375 380 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 385 390 395 400 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 405 410 415 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 420 425 430 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 435 440 445 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 450 455 460 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 465 470 475 480 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly 485 490 495 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 500 505 510 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 515 520 525 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 530 535 540 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 545 550 555 560 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 565 570 575 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 580 585 590 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 595 600 605 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 610 615 620 Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 625 630 635 640 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 645 650 655 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 660 665 670 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 675 680 685 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 690 695 700 Gly 705 <210> 243 <211> 700 <212> PRT <213> Artificial Sequence <220> <223> DLL3#9 Chain <400> 243 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Arg Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Thr Ser Pro 85 90 95 Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala 100 105 110 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 145 150 155 160 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser 210 215 220 Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly 225 230 235 240 Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Val His 245 250 255 Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser 260 265 270 Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser 275 280 285 Trp Ile Arg Gln Thr Pro Gly Lys Gly Leu Asp Trp Ile Gly Tyr Arg 290 295 300 Tyr Tyr Ser Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val 305 310 315 320 Thr Ile Ser Leu Asp Met Ser Asn Asn Gln Phe Ser Leu Lys Leu Ser 325 330 335 Ser Val Thr Ala Ala Asp Thr Ala Ile Tyr Tyr Cys Ala Ser Ile Gly 340 345 350 Val Ala Gly Phe Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr 355 360 365 Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 370 375 380 Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 385 390 395 400 Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 405 410 415 Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 420 425 430 Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 435 440 445 Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys 450 455 460 Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 465 470 475 480 Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu 485 490 495 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 500 505 510 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 515 520 525 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 530 535 540 Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 545 550 555 560 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 565 570 575 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 580 585 590 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 595 600 605 Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys 610 615 620 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 625 630 635 640 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 645 650 655 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 660 665 670 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 675 680 685 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 690 695 700 <210> 244 <211> 703 <212> PRT <213> artificial sequence <220> <223> DLL3#10 chain <400> 244 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Leu Asn Ser Ile 20 25 30 Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Trp Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Tyr Gly Gly Ser Met 85 90 95 Asn Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala 100 105 110 Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125 Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 130 135 140 Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 145 150 155 160 Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 165 170 175 Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 180 185 190 Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 195 200 205 Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser 210 215 220 Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly 225 230 235 240 Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Val Gln 245 250 255 Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys 260 265 270 Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His 275 280 285 Trp Val Arg Leu Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile 290 295 300 Asn Pro Asn Ser Gly Gly Thr Ile Phe Ala Gln Arg Phe Gln Gly Arg 305 310 315 320 Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Val Tyr Met Asp Leu 325 330 335 Asn Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp 340 345 350 Phe Gly Asp Thr Val Gly Asn Ala Phe Asp Ile Trp Gly Gln Gly Thr 355 360 365 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 370 375 380 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 385 390 395 400 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 405 410 415 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 420 425 430 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 435 440 445 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 450 455 460 Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr 465 470 475 480 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser 485 490 495 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 500 505 510 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 515 520 525 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 530 535 540 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 545 550 555 560 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 565 570 575 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 580 585 590 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 595 600 605 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Trp Cys 610 615 620 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 625 630 635 640 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 645 650 655 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 660 665 670 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 675 680 685 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 690 695 700 <210> 245 <211> 700 <212> PRT <213> Artificial sequence <220> <223> DLL3 #11 chain <400> 245 Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Thr Tyr Ile 20 25 30 His Trp Phe Gln Gln Asn Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr 35 40 45 Arg Thr Ser Tyr Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro Arg Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro 100 105 110 Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr 115 120 125 Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys 130 135 140 Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu 145 150 155 160 Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser 165 170 175 Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala 180 185 190 Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe 195 200 205 Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser Ser Gly 210 215 220 Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly Ser Gly 225 230 235 240 Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Val Gln Leu Gln 245 250 255 Gln Pro Gly Ala Glu Leu Val Gln Pro Gly Ser Ser Val Lys Met Ser 260 265 270 Cys Lys Ala Ser Gly Tyr Ala Phe Ser Asp Tyr Trp Ile Thr Trp Val 275 280 285 Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Asp Ile Tyr Pro 290 295 300 Gly Ser Gly Ser Thr Lys Ser Ser Glu Lys Phe Lys Asn Lys Ala Thr 305 310 315 320 Leu Thr Ala Asp Thr Ser Ser Ser Lys Ala Tyr Ile Gln Phe Ser Ser 325 330 335 Leu Thr Pro Glu Asp Ser Ala Val Tyr Tyr Cys Val Ser Leu Tyr Tyr 340 345 350 Tyr Gly Ser His Tyr Leu Asp Thr Trp Gly Gln Gly Thr Thr Leu Thr 355 360 365 Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 370 375 380 Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 385 390 395 400 Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 405 410 415 Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 420 425 430 Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 435 440 445 Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys 450 455 460 Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 465 470 475 480 Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu 485 490 495 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 500 505 510 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 515 520 525 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 530 535 540 Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 545 550 555 560 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 565 570 575 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 580 585 590 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 595 600 605 Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys 610 615 620 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 625 630 635 640 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 645 650 655 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 660 665 670 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 675 680 685 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 690 695 700 <210> 246 <211> 700 <212> PRT <213> Artificial sequence <220> <223> DLL3#12 chain <400> 246 Gln Val Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Thr Tyr Ile 20 25 30 His Trp Phe Gln Gln Asn Pro Gly Thr Ser Pro Lys Leu Trp Ile Tyr 35 40 45 Arg Thr Ser Tyr Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Met Glu Ala Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg Ser Ser Tyr Pro Arg Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro 100 105 110 Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr 115 120 125 Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys 130 135 140 Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu 145 150 155 160 Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser 165 170 175 Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala 180 185 190 Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe 195 200 205 Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser Ser Gly 210 215 220 Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly Ser Gly 225 230 235 240 Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Val Gln Leu Gln 245 250 255 Gln Pro Gly Ala Glu Phe Val Gln Pro Gly Ser Ser Val Lys Met Ser 260 265 270 Cys Lys Ala Ser Gly Tyr Ala Phe Ser Asp Tyr Trp Ile Thr Trp Val 275 280 285 Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Asp Ile Tyr Pro 290 295 300 Gly Ser Gly Ser Thr Lys Ser Ser Glu Lys Phe Lys Asn Arg Ala Thr 305 310 315 320 Leu Thr Ala Asp Thr Ser Ser Ser Thr Ala Tyr Ile Gln Phe Ser Ser 325 330 335 Leu Thr Pro Glu Asp Ser Ala Val Tyr Tyr Cys Val Ser Leu Tyr Tyr 340 345 350 Tyr Gly Ser Tyr Tyr Leu Asp Thr Trp Gly Gln Gly Thr Thr Leu Thr 355 360 365 Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 370 375 380 Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 385 390 395 400 Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 405 410 415 Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 420 425 430 Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 435 440 445 Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys 450 455 460 Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 465 470 475 480 Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu 485 490 495 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 500 505 510 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 515 520 525 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 530 535 540 Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 545 550 555 560 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 565 570 575 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 580 585 590 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 595 600 605 Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys 610 615 620 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 625 630 635 640 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 645 650 655 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 660 665 670 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 675 680 685 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 690 695 700 <210> 247 <211> 706 <212> PRT <213> Artificial Sequence <220> <223> DLL3#13 Chain <400> 247 Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ala Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser 210 215 220 Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly 225 230 235 240 Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly 245 250 255 Ser Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly 260 265 270 Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn 275 280 285 Tyr Gly Val Thr Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp 290 295 300 Met Gly Trp Ile Asn Thr Tyr Ser Gly Ala Pro Thr Tyr Ala Asp Asp 305 310 315 320 Phe Asn Gly Arg Phe Ala Leu Ser Leu Glu Thr Ser Ala Ser Thr Ala 325 330 335 Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe 340 345 350 Cys Ala Arg Leu Asp Asp Tyr Asp Leu Tyr Tyr Phe Asp Tyr Trp Gly 355 360 365 Gln Gly Thr Ala Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 370 375 380 Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 385 390 395 400 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 405 410 415 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 420 425 430 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 435 440 445 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 450 455 460 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 465 470 475 480 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly 485 490 495 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 500 505 510 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 515 520 525 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 530 535 540 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 545 550 555 560 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 565 570 575 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 580 585 590 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 595 600 605 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 610 615 620 Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 625 630 635 640 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 645 650 655 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 660 665 670 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 675 680 685 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 690 695 700 Pro Gly 705 <210> 248 <211> 700 <212> PRT <213> Artificial sequence <220> <223> DLL3#14 chain <400> 248 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ser Val Ser Leu Gly 1 5 10 15 Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp 20 25 30 Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Glu Ser Gly Ile Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 65 70 75 80 Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asp 85 90 95 Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 100 105 110 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 115 120 125 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 130 135 140 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 145 150 155 160 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 165 170 175 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 180 185 190 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 195 200 205 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu 210 215 220 Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys 225 230 235 240 Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser 245 250 255 Gln Ile Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Val 260 265 270 Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Ile 275 280 285 His Trp Met Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Tyr 290 295 300 Ile Tyr Pro Gly Asn Ser Tyr Thr Ala Tyr Asn Gln Lys Phe Lys Asp 305 310 315 320 Lys Ala Thr Leu Thr Ala Asp Asn Pro Ser Ser Thr Ala Tyr Met Gln 325 330 335 Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg 340 345 350 Ser Gly Gly Ser Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr 355 360 365 Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 370 375 380 Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 385 390 395 400 Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 405 410 415 Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 420 425 430 Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 435 440 445 Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys 450 455 460 Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 465 470 475 480 Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu 485 490 495 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 500 505 510 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 515 520 525 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 530 535 540 Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 545 550 555 560 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 565 570 575 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 580 585 590 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 595 600 605 Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys 610 615 620 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 625 630 635 640 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 645 650 655 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 660 665 670 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 675 680 685 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 690 695 700 <210> 249 <211> 706 <212> PRT <213> artificial sequence <220> <223> DLL3#15chain <400> 249 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp 20 25 30 Gly Asp Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 65 70 75 80 Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Ser 85 90 95 Glu Asp Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 100 105 110 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 115 120 125 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 130 135 140 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 145 150 155 160 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 165 170 175 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 180 185 190 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 195 200 205 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu 210 215 220 Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys 225 230 235 240 Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser 245 250 255 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 260 265 270 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 275 280 285 Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 290 295 300 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 305 310 315 320 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 325 330 335 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Met Ala Thr Tyr Phe Cys 340 345 350 Thr Lys Phe His Phe Ser Ser Asn Gly Asp Ala Met Asp Asn Trp Gly 355 360 365 Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 370 375 380 Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 385 390 395 400 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 405 410 415 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 420 425 430 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 435 440 445 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 450 455 460 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 465 470 475 480 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly 485 490 495 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 500 505 510 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 515 520 525 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 530 535 540 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 545 550 555 560 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 565 570 575 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 580 585 590 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 595 600 605 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 610 615 620 Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 625 630 635 640 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 645 650 655 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 660 665 670 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 675 680 685 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 690 695 700 Pro Gly 705 <210> 250 <211> 697 <212> PRT <213> artificial sequence <220> <223> DLL3#16 chain <400> 250 Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Ser Asp Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Phe Leu Ile 35 40 45 Tyr Arg Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Ala Asp Phe Ala Thr Tyr Tyr Cys Gln Leu Tyr Asn Ser Tyr Ser Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser Ser 210 215 220 Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly Ser 225 230 235 240 Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Glu Val His Leu 245 250 255 Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu 260 265 270 Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Thr Trp 275 280 285 Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys 290 295 300 Glu Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe 305 310 315 320 Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn 325 330 335 Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Asp Trp 340 345 350 Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 355 360 365 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 370 375 380 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 385 390 395 400 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 405 410 415 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 420 425 430 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 435 440 445 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 450 455 460 Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 465 470 475 480 Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 485 490 495 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 500 505 510 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 515 520 525 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 530 535 540 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 545 550 555 560 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 565 570 575 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 580 585 590 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 595 600 605 Met Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr 610 615 620 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 625 630 635 640 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 645 650 655 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 660 665 670 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 675 680 685 Gln Lys Ser Leu Ser Leu Ser Pro Gly 690 695 <210> 251 <211> 698 <212> PRT <213> Artificial Sequence <220> <223> DLL3#17 Chain <400> 251 Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ala Ala Ser Val Gly 1 5 10 15 Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Tyr Ser 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Ile 35 40 45 Tyr Asn Thr Asn Ser Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Gln Tyr Ser Met Lys Ile Asn Ser Met Gln Pro 65 70 75 80 Glu Asp Thr Ala Thr Tyr Phe Cys Lys Gln Ala Tyr Asp Phe Pro Leu 85 90 95 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser Ser 210 215 220 Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly Ser 225 230 235 240 Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Ile Gln Leu 245 250 255 Gln Gln Ser Gly Pro Glu Val Val Lys Pro Gly Ala Ser Val Lys Ile 260 265 270 Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Ser Tyr Tyr Ile His Trp 275 280 285 Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Trp Ile Tyr 290 295 300 Pro Gly Asp Gly Ser Thr Asn Asn Asn Glu Lys Phe Lys Gly Lys Thr 305 310 315 320 Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Leu Leu Ser 325 330 335 Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Gly Glu 340 345 350 Gly Asn Ala Met Asp Asp Trp Gly Gln Gly Thr Ser Val Thr Val Ser 355 360 365 Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser 370 375 380 Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp 385 390 395 400 Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr 405 410 415 Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr 420 425 430 Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln 435 440 445 Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp 450 455 460 Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro 465 470 475 480 Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro 485 490 495 Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 500 505 510 Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 515 520 525 Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 530 535 540 Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 545 550 555 560 Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 565 570 575 Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 580 585 590 Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu 595 600 605 Glu Met Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe 610 615 620 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 625 630 635 640 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 645 650 655 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 660 665 670 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 675 680 685 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 690 695 <210> 252 <211> 698 <212> PRT <213> Artificial sequence <220> <223> DLL3#18 chain <400> 252 Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ala Ala Ser Val Gly 1 5 10 15 Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Tyr Ser 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Ile 35 40 45 Tyr Asn Ala Asn Ser Leu Glu Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Gln Tyr Ser Met Lys Ile Asn Asn Met Gln Pro 65 70 75 80 Glu Asp Thr Ala Thr Tyr Phe Cys Lys Gln Ala Tyr Asp Val Pro Leu 85 90 95 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser Glu Gly Lys Ser Ser 210 215 220 Gly Ser Gly Ser Glu Ser Lys Ser Thr Glu Gly Lys Ser Ser Gly Ser 225 230 235 240 Gly Ser Glu Ser Lys Ser Thr Gly Gly Gly Gly Ser Gln Val Gln Leu 245 250 255 Gln Gln Ser Gly Pro Asp Leu Val Lys Pro Gly Ala Ser Val Lys Met 260 265 270 Ser Cys Glu Ala Ser Gly Tyr Thr Phe Thr Ala Tyr Phe Ile His Trp 275 280 285 Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Asp 290 295 300 Pro Phe Asn Asp Asp Thr Asn Tyr Asn Val Lys Phe Lys Gly Lys Ala 305 310 315 320 Thr Leu Thr Ser Asp Thr Ser Ser Ser Ile Ala Tyr Met Glu Leu Ser 325 330 335 Ser Leu Thr Ser Glu Asp Ser Ser Phe Tyr Tyr Cys Ala Arg Gly Thr 340 345 350 Ser Ala Thr Leu Asp Tyr Trp Gly His Gly Thr Thr Leu Thr Val Ser 355 360 365 Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser 370 375 380 Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp 385 390 395 400 Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr 405 410 415 Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr 420 425 430 Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln 435 440 445 Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp 450 455 460 Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro 465 470 475 480 Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro 485 490 495 Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 500 505 510 Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 515 520 525 Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 530 535 540 Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 545 550 555 560 Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 565 570 575 Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 580 585 590 Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu 595 600 605 Glu Met Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe 610 615 620 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 625 630 635 640 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 645 650 655 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 660 665 670 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 675 680 685 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 690 695 <210> 253 <211> 61 <212> PRT <213> Artificial Sequence <220> <223> Heavy chain region <400> 253 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 1 5 10 15 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 20 25 30 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 35 40 45 Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 50 55 60 <210> 254 <21l> 330 <212> PRT <213> Artificial sequence <220> <223> Mouse <400> 254 Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly 1 5 10 15 Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr 20 25 30 Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu 50 55 60 Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile 65 70 75 80 Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys 85 90 95 Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys 100 105 110 Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro 115 120 125 Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys 130 135 140 Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp 145 150 155 160 Phe Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg 165 170 175 Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln 180 185 190 His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn 195 200 205 Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly 210 215 220 Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu 225 230 235 240 Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met 245 250 255 Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu 260 265 270 Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe 275 280 285 Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn 290 295 300 Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr 305 310 315 320 Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys 325 330 <210> 255 <211> 107 <212> PRT <213> Artificial Sequence<L <220> <223> Mouse <400> 255 Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu 1 5 10 15 Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe 20 25 30 Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg 35 40 45 Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser 50 55 60 Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu 65 70 75 80 Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser 85 90 95 Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys 100 105 <210> 256 <211> 446 <212> PRT <213> Synthetic Sequence <220> <223> PD1-1 HC <400> 256 Glu Val Met Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ala Ser 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Tyr Ile Ser Gly Gly Gly Gly Asp Thr Tyr Tyr Ser Ser Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg His Ser Asn Val Asn Tyr Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro 210 215 220 Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 260 265 270 Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 445 <210> 257 <211> 218 <212> PRT <213> Artificial sequence <220> <223> PD1-1 LC <400> 257 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Met Ser Cys Arg Ala Ser Glu Asn Ile Asp Thr Ser 20 25 30 Gly Ile Ser Phe Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 35 40 45 Lys Leu Leu Ile Tyr Val Ala Ser Asn Gln Gly Ser Gly Ile Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Lys 85 90 95 Glu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg 100 105 110 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 115 120 125 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 130 135 140 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 145 150 155 160 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 165 170 175 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 180 185 190 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 195 200 205 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 258 <211> 446 <212> PRT <213> Synthetic sequence <220> <223> PD1-2 HC <400> 258 Glu Val Met Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ala Ser 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Tyr Ile Ser Gly Gly Gly Gly Asp Thr Tyr Tyr Ser Ser Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg His Ser Asn Pro Asn Tyr Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro 210 215 220 Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 260 265 270 Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 445 <210> 259 <211> 218 <212> PRT <213> Artificial sequence <220> <223> PD1-2 LC <400> 259 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Met Ser Cys Arg Ala Ser Glu Asn Ile Asp Thr Ser 20 25 30 Gly Ile Ser Phe Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 35 40 45 Lys Leu Leu Ile Tyr Val Ala Ser Asn Gln Gly Ser Gly Ile Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Lys 85 90 95 Glu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg 100 105 110 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 115 120 125 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 130 135 140 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 145 150 155 160 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 165 170 175 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 180 185 190 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 195 200 205 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 260 <211> 446 <212> PRT <213> Synthetic sequence <220> <223> PD1-3 HC <400> 260 Glu Val Met Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 01 5 10 15 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Lys Ser 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Tyr Ile Ser Gly Gly Gly Gly Asp Thr Tyr Tyr Ser Ser Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg His Ser Asn Val Asn Tyr Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro 210 215 220 Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 260 265 270 Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 445 <210> 261 <211> 218 <212> PRT <213> Artificial Sequence <220> <223> PD1-3 LC <400> 261 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Met Ser Cys Arg Ala Ser Glu Asn Ile Asp Val Ser 20 25 30 Gly Ile Ser Phe Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 35 40 45 Lys Leu Leu Ile Tyr Val Ala Ser Asn Gln Gly Ser Gly Ile Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Lys 85 90 95 Glu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg 100 105 110 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 115 120 125 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 130 135 140 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 145 150 155 160 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 165 170 175 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 180 185 190 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 195 200 205 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 262 <211> 446 <212> PRT <213> Artificial sequence <220> <223> PD1-4 HC <400> 262 Glu Val Met Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Lys Ser 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Tyr Ile Ser Gly Gly Gly Gly Asp Thr Tyr Tyr Ser Ser Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg His Ser Asn Val Asn Tyr Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro 210 215 220 Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 260 265 270 Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 445 <210> 263 <211> 218 <212> PRT <213> Artificial sequence <220> <223> PD1-4 LC <400> 263 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Met Ser Cys Arg Ala Ser Glu Asn Ile Asp Val Ser 20 25 30 Gly Ile Ser Phe Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 35 40 45 Lys Leu Leu Ile Tyr Val Ala Ser Asn Gln Gly Ser Gly Ile Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Lys 85 90 95 Glu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg 100 105 110 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 115 120 125 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 130 135 140 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 145 150 155 160 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 165 170 175 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 180 185 190 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 195 200 205 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 264 <211> 446 <212> PRT <213> Synthetic sequence <220> <223> PD1-5 HC <400> 264 Glu Val Met Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Lys Ser 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Tyr Ile Ser Gly Gly Gly Gly Asp Thr Tyr Tyr Ser Ser Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg His Ser Asn Val Asn Tyr Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro 210 215 220 Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 260 265 270 Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 445 <210> 265 <211> 218 <212> PRT <213> Synthetic Sequence <220> <223> PD1-5 LC <400> 265 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Met Ser Cys Arg Ala Ser Glu Asn Ile Asp Val Ser 20 25 30 Gly Ile Ser Phe Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 35 40 45 Lys Leu Leu Ile Tyr Val Ala Ser Asn Gln Gly Ser Gly Ile Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Lys 85 90 95 Glu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg 100 105 110 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 115 120 125 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 130 135 140 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 145 150 155 160 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 165 170 175 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 180 185 190 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 195 200 205 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215

Brief Description of the Drawings

[0070] Figure 1 : Schematic diagram of the bispecific binding protein of the present invention

[0071] Figure 2 : Schematic diagram of DLL3 full-length protein and DLL3 domain constructs expressed in HEK293 cells for epitope domain mapping. For the DLL3 domain construct, the transmembrane and intracellular domains are derived from EpCAM.

[0072] Figure 3A Figure 3: DLL3 epitope domain mapping of seven exemplary DLL3 / CD3 binding proteins. Exemplary DLL3 / CD3 binding proteins recognize the membrane-proximal peptides EGF4, EGF1, and DSL domains of DLL3. The y-axis plots counts, and the x-axis plots PE-A (phycoerythrin signal region).

[0073] Figure 3B Figure 2: DLL3 epitope domain mapping of six exemplary DLL3 / CD3 binding proteins. Exemplary DLL3 / CD3 binding proteins recognize EGF1, EGF3, EGF4, or EGF6 of DLL3. The y-axis depicts counts and the x-axis depicts PE-A (phycoerythrin signal).

[0074] Figure 3C Figure 2: DLL3 epitope domain mapping of six exemplary DLL3 / CD3 binding proteins. Exemplary DLL3 / CD3 binding proteins recognize the DSL domain or neither DSL, EGF, nor the membrane-proximal peptide of DLL3. The y-axis plots counts, and the x-axis plots PE-A (phycoerythrin signal).

[0075] Figure 4 : Binding of seven exemplary DLL3 / CD3 binding proteins to cell lines expressing human and cynomolgus macaque DLL3. The y-axis depicts counts and the x-axis depicts PE-A (phycoerythrin signal area).

[0076] Figure 5 Figure 2: Binding of seven exemplary DLL3 / CD3 binding proteins to cell lines expressing human DLL1 and DLL4. No binding to human DLL1 and DLL4 was detected. The y-axis depicts counts and the x-axis depicts PE-A (phycoerythrin signal area).

[0077] Figure 6A : Binding of seven exemplary DLL3 / CD3 binding proteins to SCLC cell lines and human T cells analyzed by flow cytometry.

[0078] Figure 6B : Binding of exemplary DLL3 / CD3 binding proteins (to peptides other than DSL, EGF1-6, and membrane-proximal peptides) to SHP77 cells.

[0079] Figure 6C : Binding of exemplary DLL3 / CD3 binding proteins (directed to the DSL domain) to SHP77 cells.

[0080] Figure 6D : Binding of exemplary DLL3 / CD3 binding proteins (directed to the EGF1 domain) to SHP77 cells.

[0081] Figure 6E : Binding of exemplary DLL3 / CD3 binding proteins (directed to the EGF3 domain) to SHP77 cells.

[0082] Figure 6F : Binding of exemplary DLL3 / CD3 binding proteins (directed to the EGF4 domain) to SHP77 cells.

[0083] Figure 6G : Binding of exemplary DLL3 / CD3 binding proteins (directed to the DSL domain) to SHP77 cells.

[0084] Figure 6H : Binding of exemplary DLL3 / CD3 binding proteins (directed against the membrane-proximal peptide domain) to SHP77 cells.

[0085] Figure 6I : Binding of exemplary DLL3 / CD3 binding proteins (directed against peptides other than DSL, EGF1-6, and membrane-proximal peptides) to NCI-H82 cells.

[0086] Figure 6J : Binding of exemplary DLL3 / CD3 binding proteins (directed to the DSL domain) to NCI-H82 cells.

[0087] Figure 6K : Binding of exemplary DLL3 / CD3 binding proteins (directed to the EGF1 domain) to NCI-H82 cells.

[0088] Figure 6L : Binding of exemplary DLL3 / CD3 binding proteins (directed to the EGF3 domain) to NCI-H82 cells.

[0089] Figure 6M : Binding of exemplary DLL3 / CD3 binding proteins (directed to the EGF4 domain) to NCI-H82 cells.

[0090] Figure 6N : Binding of exemplary DLL3 / CD3 binding proteins (directed to the DSL domain) to NCI-H82 cells.

[0091] Figure 6O : Binding of exemplary DLL3 / CD3 binding proteins (directed against the membrane-proximal peptide domain) to NCI-H82 cells.

[0092] Figure 6P : Binding of exemplary DLL3 / CD3 binding proteins (to peptides other than DSL, EGF1-6, and membrane-proximal peptides) to T cells.

[0093] Figure 6Q : Binding of exemplary DLL3 / CD3 binding proteins (directed to the DSL domain) to T cells.

[0094] Figure 6R : Binding of exemplary DLL3 / CD3 binding proteins (directed to the EGF1 domain) to T cells.

[0095] Figure 6S : Binding of exemplary DLL3 / CD3 binding proteins (directed to the EGF3 domain) to T cells.

[0096] Figure 6T : Binding of exemplary DLL3 / CD3 binding proteins (directed to the EGF4 domain) to T cells.

[0097] Figure 6U : Binding of exemplary DLL3 / CD3 binding proteins (directed to the EGF6 domain) to T cells.

[0098] Figure 6V : Binding of exemplary DLL3 / CD3 binding proteins (directed to the membrane-proximal peptide domain) to T cells.

[0099] Figure 7A : Efficacy of seven DLL3 / CD3 binding proteins in lysing non-stimulated PBMCs redirected to human SCLC cell lines.

[0100] Figure 7B : Efficacy of exemplary DLL3 / CD3 binding proteins (directed to peptides other than DSL, EGF1-6, or membrane-proximal peptides) in redirecting non-stimulatory T cells to human SHP77 cells in lysing cells.

[0101] Figure 7C : Efficacy of exemplary DLL3 / CD3 binding proteins (directed to the DSL domain) in lysing non-stimulatory T cells redirected to human SHP77 cells.

[0102] Figure 7D : Efficacy of exemplary DLL3 / CD3 binding proteins (directed against the EGF1 domain) in lysing non-stimulatory T cells redirected to human SHP77 cells.

[0103] Figure 7E : Efficacy of exemplary DLL3 / CD3 binding proteins (directed against the EGF3 domain) in lysing non-stimulatory T cells redirected to human SHP77 cells.

[0104] Figure 7F : Efficacy of exemplary DLL3 / CD3 binding proteins (directed against the EGF4 domain) in lysing non-stimulatory T cells redirected to human SHP77 cells.

[0105] Figure 7G : Efficacy of exemplary DLL3 / CD3 binding proteins (directed against the EGF6 domain) in lysing non-stimulatory T cells redirected to human SHP77 cells.

[0106] Figure 7H : Efficacy of exemplary DLL3 / CD3 binding proteins (directed against membrane-proximal peptides) in lysing human SHP77 cells to redirect non-stimulatory T cells.

[0107] Figure 7I : Efficacy of exemplary DLL3 / CD3 binding proteins (directed against peptides other than DSL, EGF1-6, or membrane-proximal peptides) in lysing non-stimulatory T cells directed to human NCI-H82 cells.

[0108] Figure 7J : Efficacy of exemplary DLL3 / CD3 binding proteins (directed against the DSL domain) in lysing non-stimulatory T cells redirected to human NCI-H82 cells.

[0109] Figure 7K : Efficacy of exemplary DLL3 / CD3 binding proteins (directed against the EGF1 domain) in lysing non-stimulatory T cells redirected to human NCI-H82 cells.

[0110] Figure 7L : Efficacy of exemplary DLL3 / CD3 binding proteins (directed against the EGF3 domain) in lysing non-stimulatory T cells redirected to human NCI-H82 cells.

[0111] Figure 7M : Efficacy of exemplary DLL3 / CD3 binding proteins (directed against the EGF4 domain) in lysing non-stimulatory T cells redirected to human NCI-H82 cells.

[0112] Figure 7N : Efficacy of exemplary DLL3 / CD3 binding proteins (directed against the EGF6 domain) in lysing non-stimulatory T cells redirected to human NCI-H82 cells.

[0113] Figure 7O: Efficacy of exemplary DLL3 / CD3 binding proteins (directed against membrane-proximal peptides) in lysing non-stimulatory T cells redirected to human NCI-H82 cells.

[0114] Figure 8 In vitro internalization using two exemplary DLL3 / CD3 binding proteins. DLL3 / CD3 binding proteins were pre-incubated with DLL3-positive SHP77 cells for 2 and 4 hours, followed by co-incubation with human PBMCs for 48 hours.

[0115] Figure 9 : Pharmacokinetics of two exemplary DLL3 / CD3 binding proteins. Mean pharmacokinetic profiles of DLL3#3 / CD3#1 (open squares) and DLL3#3 / CD3#2 (closed squares) in male C57BL / 6 mice after a single 1 mg / kg intravenous dose.

[0116] Figure 10 : Anti-tumor activity of two exemplary DLL3 / CD3 binding proteins. The y-axis depicts median tumor volume and the x-axis depicts time.

[0117] Figure 11 : Efficacy of exemplary DLL3 / CD3 binding proteins in lysing non-stimulated PBMCs redirected to human SHP77 and RKO-E6 cells.

[0118] Figure 12 : Potency of exemplary DLL3 / CD3 binding proteins on T cell activation in the presence of SHP77 cells

[0119] Figure 13 : Efficacy of exemplary DLL3 / CD3 binding proteins on T cell degranulation in the presence of SHP77 cells

[0120] Figure 14A : Efficacy of exemplary DLL3 / CD3 binding proteins on interferon secretion by PBMCs in the presence of SHP77 cells

[0121] Figure 14B : Efficacy of exemplary DLL3 / CD3 binding proteins on MCP-1 secretion by PBMCs in the presence of SHP77 cells

[0122] Figure 15 : Efficacy of exemplary DLL3 / CD3 binding proteins on T cell proliferation in the presence of SHP77 cells

[0123] Figure 16 : Efficacy of exemplary DLL3 / CD3 binding proteins in redirecting non-stimulatory pan T cells and naive T cells to human SHP77 in lysing cells.

[0124] Figure 17 :Non-stimulatory CD4 + and CD4 + Efficacy of exemplary DLL3 / CD3 binding proteins in lysing central memory T cells redirected to human SHP77 cells

[0125] Figure 18 :Non-stimulatory CD4 + and CD4 + Efficacy of exemplary DLL3 / CD3 binding proteins for redirecting effector memory T cells to human SHP77 in lytic cells

[0126] Figure 19 :Non-stimulatory CD8 + and CD8 + CD45RA + Efficacy of exemplary DLL3 / CD3 binding proteins for redirecting effector memory T cells to human SHP77 in lytic cells

[0127] Figure 20 :Non-stimulatory CD8 + and CD8 + Efficacy of exemplary DLL3 / CD3 binding proteins for redirecting memory T cells to human SHP77 in lytic cells

[0128] Figure 21 : T cell infiltration in SHP77 xenograft tumor tissue with exemplary DLL3 / CD3 binding proteins.

[0129] Figure 22 : Binding of three exemplary anti-DLL3 antibodies to recombinant DLL3 protein in an ELISA assay. The y-axis depicts counts and the x-axis depicts the concentration of DLL3 protein.

[0130] Figure 23 : Binding of exemplary anti-DLL3 antibodies to DLL3-positive SCLC cell lines as measured by flow cytometry. The y-axis depicts counts and the x-axis depicts the concentration of the anti-DLL3 antibody.

[0131] Figure 24 Representative staining of SCLC tissue samples with five exemplary anti-DLL3 antibodies. Anti-DLL3 antibodies DLL3#1 and DLL3#5 show tumor cells exhibiting punctate and / or diffuse cytoplasmic and / or membranous DLL3 staining. Images were generated electronically using a LEICAS CN400 automated scanner at 10× magnification.

[0132] Figure 25 : Representative staining of cell aggregates from SCLC cell lines with different DLL3 expression levels. Anti-DLL3 antibody DLL3#5 [Detailed description of the invention]

[0134] Terms and definitions used

[0135] The above and other aspects and embodiments of the present invention will become apparent from the further description herein, in which:

[0136] Unless otherwise specified or defined, all terms used have their common meanings in the art, which will be clear to those skilled in the art. For example, reference is made to standard manuals, such as Sambrook et al., "Molecular Cloning: A Laboratory Manual" (2nd edition), Volumes 1-3, Cold Spring Harbor Laboratory Press (1989); Lewin, "Genes IV", Oxford University Press, New York, (1990) and Roitt et al., "Immunology" (2nd edition), Gower Medical Publishing, London, New York (1989), and the general background technology cited herein. In addition, as will be clear to those skilled in the art, unless otherwise specified, all methods, steps, techniques and operations not specifically described in detail can be carried out in a manner known per se and have been carried out in a manner known per se. In addition, reference is made to standard manuals, the general prior art mentioned above and other references cited therein for the embodiments.

[0137] When used herein, the term "comprising" and variations thereof, such as "comprises" and "comprise" may be replaced by the terms "containing" or "including" or "having".

[0138] Unless the context requires a more restricted interpretation, the term "sequence" as used herein (e.g., such as the following terms, "heavy chain / light chain sequence", "antibody sequence", "variable domain sequence", "constant domain sequence" or "protein sequence") should generally be understood to include the relevant amino acid sequence as well as the nucleic acid sequence or nucleotide sequence encoding the same.

[0139] As used herein, "antigen binding unit" refers to a polypeptide that is capable of binding to its specific target or antigen and comprises the minimum structural requirements derived from an antibody (usually present in an antibody) that allow target binding. Thus, an antigen binding unit comprises at least three light chain and three heavy chain CDR sequences, preferably at least a light chain variable domain and a heavy chain variable domain.

[0140] The general structure of antibodies or immunoglobulins is well known to those skilled in the art. These molecules are heterotetrameric glycoproteins, typically about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains and are commonly referred to as full-length antibodies. Each light chain is covalently linked to a heavy chain via a disulfide bond to form a heterodimer, and the heterotetrameric molecule is formed via covalent disulfide bonds between the two identical heavy chains of the heterodimer. Although the light and heavy chains are linked together by a disulfide bond, the number of disulfide bonds between the two heavy chains varies depending on the immunoglobulin isotype. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has a variable domain (VH) at the N-terminus, followed by three or four (for IgE) constant domains (CH1, CH2, CH3 and CH4), and a hinge region between CH1 and CH2. Each light chain has two domains: an N-terminal variable domain (VL) and a C-terminal constant domain (CL). The VL domain is non-covalently associated with the VH domain, whereas the CL domain is typically covalently linked to the CH1 domain via a disulfide bond. Specific amino acid residues are known to form an interface between the light chain variable domain and the heavy chain variable domain (Chothia et al., 1985, J. Mol. Biol. 186: 651-663). The variable domain is also referred to herein as a variable region or Fv and represents the portion of the antibody that confers specificity for the antigen by carrying the antigen-binding site.

[0141] As used herein, "light chain variable domains" (or "light chain variable regions") and "heavy chain variable domains" (or "heavy chain variable regions") have the same general structure and each domain is essentially composed of four framework (FR) regions, the sequences of which are widely conserved and are referred to in the art and hereinafter as "framework region 1" or "FR1"; "framework region 2" or "FR2"; "framework region 3" or "FR3"; and "framework region 4" or "FR4", respectively; interspersed between the frameworks are three hypervariable regions (HVRs) (or CDRs), which are referred to in the art and hereinafter as "complementarity determining region 1" or "CDR1"; "complementarity determining region 2" or "CDR2"; and "complementarity determining region 3" or "CDR3", respectively. Thus, the general structure or sequence of an immunoglobulin variable domain can be represented as follows: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. The framework regions adopt a β-sheet configuration and the CDRs can form loops connecting the β-sheet structure. The CDRs in each chain are held in their three-dimensional structure by the framework regions and form the antigen binding site together with the CDRs from the other chain.

[0142] Within the context of the present invention, reference to the CDRs is to the CCG-based, also known as IMGT, definition (Lefranc MP, Pommie C, Ruiz M, Giudicelli V, Foulquier E, Truong L, Thouvenin-Contet V, Lefranc G. "IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains." Dev Comp Immunol. 2003 Jan;27(1):55-77; Giudicelli V, Brochet X, Lefranc MP. "IMGT / V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences". Cold Spring Harb Protoc. 2011;2011(6):695-715). Alternative definitions of CDRs known in the art are based on Chothia (Chothia and Lesk, J. Mol. Biol. 1987, 196:901-917) and Kabat (EA Kabat, TT Wu, H. Bilofsky, M. Reid-Miller and H. Perry, Sequence of Proteins of Immunological Interest, National Institutes of Health, Bethesda (1983)).

[0143] As used herein, the term "constant domain" or "constant region" refers to the sum of the domains of an antibody excluding the variable region. Such constant domains and regions are well known in the art and are described, for example, by Kabat et al. ("Sequence of proteins of immunological interest", US Public Health Services, NIH Bethesda, MD, Publication No. 91).

[0144] The "Fc portion" or "Fc domain" of an antibody is not directly involved in the binding of the antibody to the antigen, but exhibits various effector functions. "Fc portion / domain of an antibody" is a term well known to those skilled in the art and is defined on the basis of papain cleavage of the antibody. Depending on the amino acid sequence of the constant region of its heavy chain, antibodies or immunoglobulins are divided into the following classes: IgA, IgD, IgE, IgG, and IgM. Depending on the heavy chain constant region, different classes of immunoglobulins are referred to as α, δ, ε, γ, and μ, respectively. Some of these can be further divided into subclasses (isotypes), such as IgG1, IgG2, IgG3, and IgG4, IgA1, and IgA2. The Fc portion of an antibody is directly involved in ADCC (antibody-dependent cell-mediated cytotoxicity) and CDC (complement-dependent cytotoxicity), based on complement activation, C1q binding, and Fc substrate binding. Complement activation (CDC) is initiated by the binding of complement factor C1q to the Fc portion of most IgG antibody subclasses. While the effects of antibodies on the complement system depend on certain conditions, C1q binding is due to defined binding sites within the Fc portion. These binding sites are, for example, L234, L235, D270, N297, E318, K320, K322, P331, and P329 (numbered according to EU numbering (Edelman et al., Proc Natl Acad Sci USA. 1969 May;63(1):78-85). The most critical of these residues in mediating C1q and Fcγ substrate binding in IgG1 are L234 and L235 (Hezareh et al., J. Virology 75 (2001) 12161-12168, Shields et al., (2001) JBC, 276(9):6591-6604). Antibodies of the subclasses IgG1 and IgG3 typically display complement activation and binding to C1q and C3, whereas IgG2 and IgG4 do not activate the complement system and do not bind C1q and C3.

[0145] The term "antibody" or "antibody molecule" (used synonymously herein) encompasses monoclonal antibodies, polyclonal antibodies, human antibodies, humanized antibodies, chimeric antibodies, multispecific antibodies (e.g., bispecific antibodies), antibody fragments (especially Fv, Fab, Fab' or F(ab')2 fragments), single-chain antibodies (especially single-chain variable fragments (scFv), single-chain Fab fragments (scFab)), small modular immunopharmaceuticals (SMIPs), domain antibodies, nanobodies, and bifunctional antibodies. The antibody may have effector functions, such as ADCC or CDC, which are generally mediated by the Fc portion (antibody constant region) of the antibody, or it may not have effector functions, for example, by lacking an Fc portion or having a blocking, masked Fc portion, essentially an Fc portion that is not recognized or not fully recognized by immune cells or immune system components (e.g., the complement system).

[0146] Monoclonal antibodies (mAbs) are monospecific antibodies with identical amino acid sequences. They can be prepared by hybridoma technology from hybrid cell lines (called hybridomas), which represent pure lines of fusion of B cells producing specific antibodies with myeloma (B cell cancer) cells (Kohler G, Milstein C. Continuous cultures of fused cells secreting antibodies of predefined specificity. Nature 1975; 256: 495-7). Alternatively, monoclonal antibodies can be prepared by recombinant expression in host cells (Norderhaug L, Olafsen T, Michaelsen TE, Sandlie I. (May 1997). "Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells." J Immunol Methods 204 (1): 77-87; see also below). "Recombinant antibodies" or "recombinant binding proteins" are antibodies or binding proteins that have been produced by recombinantly engineered host cells. They are optionally isolated or purified.

[0147] Full-length antibodies can be treated with enzymes such as papain or pepsin to produce useful antibody fragments. Papain digestion produces two identical antigen-binding antibody fragments, called "Fab" fragments, each with a single antigen-binding site, and a residual "Fc" fragment. The Fab fragment also contains the constant domain of the light chain and the CH1 domain of the heavy chain. Pepsin treatment produces a F(ab')2 fragment, which has two antigen-binding sites and is still capable of cross-linking antigen.

[0148] Fab' fragments differ from Fab fragments by the presence of additional residues at the C-terminus of the CH1 domain, including one or more cysteines from the antibody hinge region. F(ab')2 antibody fragments are pairs of Fab' fragments linked by cysteine ​​residues in the hinge region. Other chemical couplings of antibody fragments are also known.

[0149] The "Fv" fragment contains a complete antigen recognition and binding site consisting of a dimer of one heavy-chain variable domain and one light-chain variable domain in tight, non-covalent association. In this configuration, the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody.

[0150] "Single-chain Fv" or "scFv" antibody fragments are single-chain Fv variants comprising the VH and VL domains of an antibody, wherein the domains are present in a single polypeptide chain. Single-chain Fvs are capable of recognizing and binding to antigens. ScFv polypeptides may also optionally contain a polypeptide linker between the VH and VL domains to facilitate formation of the three-dimensional structure required for antigen binding by the scFv (see, e.g., Pluckthun, 1994, The Pharmacology of monoclonal Antibodies, Vol. 113, Rosenburg and Moore, eds., Springer-Verlag, New York, pp. 269-315).

[0151] "Single-chain Fab" or "scFab" antibody fragments are single-chain Fab variants comprising the VL, CL, VH, and CH1 domains of an antibody, wherein these domains are present in a single polypeptide chain. Single-chain Fabs are capable of recognizing and binding antigen. ScFab polypeptides may also optionally contain a polypeptide linker between the CL and VH domains (Hust et al., (2007) BMC Biotechnology).

[0152] For use in humans, it is often necessary to reduce the immunogenicity of therapeutic molecules (such as antibodies or binding proteins comprising antigen binding units as described herein) that were originally derived from other species, such as mice. This can be accomplished by constructing chimeric antibodies / binding proteins, or by a method known as "humanization." In this context, "chimeric antibodies" or "chimeric antigen binding units" are understood to be antibodies or antigen binding units that comprise sequence portions (e.g., variable domains) derived from one species (e.g., mouse) fused to sequence portions (e.g., constant domains) derived from a different species (e.g., human). In this context, "humanized antibodies," "humanized binding proteins," or "humanized antigen binding units" are antibodies, proteins, or antigen binding units that comprise variable domains originally derived from non-human species, in which certain amino acids have been mutated to make the overall sequence of the variable domains more similar to the sequence of human variable domains. Methods for antibody humanization are well known in the art (Billetta R, Lobuglio AF. “Chimeric antibodies”. Int Rev Immunol. 1993; 10(2-3): 165-76; Riechmann L, Clark M, Waldmann H, Winter G (1988). “Reshaping human antibodies for therapy”. Nature: 332: 323).

[0153] "Optimized antibodies" or "optimized antigen-binding units or proteins" are specific types of humanized antibodies or humanized antigen-binding units / proteins that include immunoglobulin amino acid sequence variants or fragments thereof, which are capable of binding to a predetermined antigen and comprise one or more FRs that substantially have the amino acid sequence of a human immunoglobulin and one or more CDRs that substantially have the amino acid sequence of a non-human immuno...

Claims

1. A protein comprising a first antigen-binding unit that specifically binds to DLL3 and a second antigen-binding unit that specifically binds to CD3, Wherein the first antigen binding unit that specifically binds to DLL3 is selected from the group consisting of i) to iii): i) an antigen-binding unit comprising the following: an amino acid sequence of SEQ ID NO: 1 as a light chain CDR1, SEQ ID NO: 2 as a light chain CDR2, and SEQ ID NO: 3 as a light chain CDR3; and an amino acid sequence of SEQ ID NO: 4 as a heavy chain CDR1, SEQ ID NO: 5 as a heavy chain CDR2, and SEQ ID NO: 6 as a heavy chain CDR3; ii) an antigen-binding unit comprising the following: the amino acid sequence of SEQ ID NO: 7 as the light chain CDR1, SEQ ID NO: 8 as the light chain CDR2 and SEQ ID NO: 9 as the light chain CDR3; and the amino acid sequence of SEQ ID NO: 10 as the heavy chain CDR1, SEQ ID NO: 11 as the heavy chain CDR2 and SEQ ID NO: 12 as the heavy chain CDR3; and iii) an antigen-binding unit comprising the following: the amino acid sequence of SEQ ID NO: 13 as the light chain CDR1, SEQ ID NO: 14 as the light chain CDR2, and SEQ ID NO: 15 as the light chain CDR3; and the amino acid sequence of SEQ ID NO: 16 as the heavy chain CDR1, SEQ ID NO: 17 as the heavy chain CDR2, and SEQ ID NO: 18 as the heavy chain CDR3; and The second antigen binding unit that specifically binds to CD3 comprises: i) an antigen-binding unit comprising the following: the amino acid sequence of SEQ ID NO: 55 as the light chain CDR1, SEQ ID NO: 56 as the light chain CDR2, and SEQ ID NO: 57 as the light chain CDR3; and the amino acid sequence of SEQ ID NO: 58 as the heavy chain CDR1, SEQ ID NO: 59 as the heavy chain CDR2, and SEQ ID NO: 60 as the heavy chain CDR3; or ii) an antigen-binding unit comprising the following: the amino acid sequence of SEQ ID NO:61 as the light chain CDR1, SEQ ID NO:62 as the light chain CDR2 and SEQ ID NO:63 as the light chain CDR3; and the amino acid sequence of SEQ ID NO:64 as the heavy chain CDR1, SEQ ID NO:65 as the heavy chain CDR2 and SEQ ID NO:66 as the heavy chain CDR3.

2. The protein of claim 1, wherein i) the first antigen binding unit that specifically binds to DLL3 comprises, from its N-terminus to its C-terminus, a first light chain variable domain, a first light chain constant domain, a first peptide linker, a first heavy chain variable domain, and a first heavy chain constant CH1 domain; and ii) The second antigen binding unit that specifically binds to CD3 comprises, from its N-terminus to its C-terminus, a second light chain variable domain, a second light chain constant domain, a second peptide linker, a second heavy chain variable domain and a second heavy chain constant CH1 domain.

3. The protein of claim 2, wherein The first antigen binding unit comprises: the amino acid sequence of SEQ ID NO: 13 as the light chain CDR1, SEQ ID NO: 14 as the light chain CDR2 and SEQ ID NO: 15 as the light chain CDR3, and the amino acid sequence of SEQ ID NO: 16 as the heavy chain CDR1, SEQ ID NO: 17 as the heavy chain CDR2 and SEQ ID NO: 18 as the heavy chain CDR3, and the second antigen binding unit comprises: the amino acid sequence of SEQ ID NO: 55 as the light chain CDR1, SEQ ID NO: 56 as the light chain CDR2 and SEQ ID NO: 57 as the light chain CDR3, and the amino acid sequence of SEQ ID NO: 58 as the heavy chain CDR1, SEQ ID NO: 59 as the heavy chain CDR2 and SEQ ID NO: 60 as the heavy chain CDR3.

4. The protein of claim 2, further comprising first and second Fc domains, the first Fc domain being covalently linked to the first antigen binding unit, and the second Fc domain being covalently linked to the second antigen binding unit.

5. The protein of claim 4, wherein i) the first Fc domain comprises a tyrosine (Y) at position 366 [T366Y], and the second Fc domain comprises a threonine (T) at position 407 [Y407T], or ii) the first Fc domain comprises a tryptophan (W) at position 366 [T366W], and the second Fc domain comprises a serine (S) at position 366 [T366S], an alanine (A) at position 368 [L368A] and a valine (V) at position 407 [Y407V], or iii) the second Fc domain comprises a tyrosine (Y) at position 366 [T366Y], and the first Fc domain comprises a threonine (T) at position 407 [Y407T], or iv) the second Fc domain comprises a tryptophan (W) at position 366 [T366W], and the first Fc domain comprises a serine (S) at position 366 [T366S], an alanine (A) at position 368 [L368A] and a valine (V) at position 407 [Y407V], The amino acid numbering is according to the EU numbering system.

6. The protein of claim 5, wherein the first and / or the second Fc domain further comprises an alanine at position 234 [L234A] and an alanine at position 235 [L235A], wherein the numbering of amino acids is according to the EU numbering system.

7. An isolated nucleic acid molecule encoding a first antigen binding unit of a protein according to any one of claims 1 to 6, which optionally further encodes a second antigen binding unit, a first Fc domain and / or a second Fc domain of said protein.

8. An expression vector comprising the nucleic acid molecule according to claim 7.

9. A host cell transfected with the expression vector according to claim 8.

10. A method for producing a protein according to any one of claims 1 to 6, comprising i) cultivating a host cell according to claim 9 under conditions which allow the expression of a protein according to any one of claims 1 to 6; and, ii) recovering the protein; and optionally iii) further purifying and / or modifying and / or formulating the protein.

11. A protein comprising a first polypeptide chain that specifically binds to DLL3 and a second polypeptide chain that specifically binds to CD3, wherein the first polypeptide chain comprises a first light chain, a first peptide linker, and a first heavy chain, and the second polypeptide chain comprises a second light chain, a second peptide linker, and a second heavy chain; and wherein the first polypeptide chain that specifically binds to DLL3 comprises a light chain variable domain and a heavy chain variable domain, in: i) the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 1 as CDR1, SEQ ID NO: 2 as CDR2 and SEQ ID NO: 3 as CDR3; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 4 as CDR1, SEQ ID NO: 5 as CDR2 and SEQ ID NO: 6 as CDR3; ii) the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 7 as CDR1, SEQ ID NO: 8 as CDR2 and SEQ ID NO: 9 as CDR3; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 10 as CDR1, SEQ ID NO: 11 as CDR2 and SEQ ID NO: 12 as CDR3; or iii) the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13 as CDR1, SEQ ID NO: 14 as CDR2 and SEQ ID NO: 15 as CDR3; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 16 as CDR1, SEQ ID NO: 17 as CDR2 and SEQ ID NO: 18 as CDR3; And wherein the second polypeptide chain that specifically binds to CD3 comprises a light chain variable domain and a heavy chain variable domain, wherein: i) the light chain variable domain comprises the amino acid sequence of SEQ ID NO:55 as CDR1, SEQ ID NO:56 as CDR2 and SEQ ID NO:57 as CDR3; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:58 as CDR1, SEQ ID NO:59 as CDR2 and SEQ ID NO:60 as CDR3; or ii) the light chain variable domain comprises the amino acid sequence of SEQ ID NO:61 as CDR1, SEQ ID NO:62 as CDR2 and SEQ ID NO:63 as CDR3; and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:64 as CDR1, SEQ ID NO:65 as CDR2 and SEQ ID NO:66 as CDR3.

12. The protein of claim 11, wherein the C-terminus of the first light chain is covalently linked to the N-terminus of the first heavy chain via the first peptide linker, and wherein the C-terminus of the second light chain is covalently linked to the N-terminus of the second heavy chain via the second peptide linker.

13. The protein of claim 11, wherein The first polypeptide chain that specifically binds to DLL3 comprises a light chain variable domain and a heavy chain variable domain, in: The light chain variable domain comprises the amino acid sequence of SEQ ID NO: 13 as CDR1, SEQ ID NO: 14 as CDR2 and SEQ ID NO: 15 as CDR3, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 16 as CDR1, SEQ ID NO: 17 as CDR2 and SEQ ID NO: 18 as CDR3; and the second polypeptide chain that specifically binds to CD3 comprises a light chain variable domain and a heavy chain variable domain, wherein: the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 55 as CDR1, SEQ ID NO: 56 as CDR2 and SEQ ID NO: 57 as CDR3, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 58 as CDR1, SEQ ID NO: 59 as CDR2 and SEQ ID NO: 60 as CDR3.

14. The protein of claim 11, wherein i) the first heavy chain comprises a tyrosine (Y) at position 366 [T366Y], and the second heavy chain comprises a threonine (T) at position 407 [Y407T], or ii) the first heavy chain comprises a tryptophan (W) at position 366 [T366W], and the second heavy chain comprises a serine (S) at position 366 [T366S], an alanine (A) at position 368 [L368A], and a valine (V) at position 407 [Y407V], or iii) the second heavy chain comprises a tyrosine (Y) at position 366 [T366Y], and the first heavy chain comprises a threonine (T) at position 407 [Y407T], or iv) the second heavy chain comprises a tryptophan (W) at position 366 [T366W], and the first heavy chain comprises a serine (S) at position 366 [T366S], an alanine (A) at position 368 [L368A], and a valine (V) at position 407 [Y407V], The amino acid numbering is according to the EU numbering system.

15. The protein of claim 14, wherein the first and / or the second heavy chain further comprises an alanine at position 234 [L234A] and an alanine at position 235 [L235A], wherein the numbering of amino acids is according to the EU numbering system.

16. A pharmaceutical composition comprising the protein of any one of claims 1 to 6 or 11 to 15 and a pharmaceutically acceptable carrier.

17. Use of a protein according to any one of claims 1 to 6 or 11 to 15 for the preparation of a pharmaceutical composition for the treatment of SCLC, glioblastoma or a neuroendocrine tumor expressing DLL3.

18. The use of claim 17, wherein the protein is used in combination with a chemotherapeutic agent, a therapeutically active compound that inhibits angiogenesis, a signal transduction pathway inhibitor, an EGFR inhibitor, an immunomodulator, an immune checkpoint inhibitor, or a hormone therapy agent.

19. The use according to claim 18, wherein the protein is used in combination with an immune checkpoint inhibitor, and the immune checkpoint inhibitor is an anti-PD-1 antibody or an anti-PD-L1 antibody.